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ABSTRACT 
The fundamental vibrational modes of biological constituents in the tissues and the 
complex body fluids coincide with optical frequencies in the infrared region. Therefore, spatially 
resolved molecular compositions and interaction information within the biological materials can 
be extracted non-destructively using IR radiation without the use of labels or probes. However, the 
feasibility of this technique to elucidate constituent molecular compositions and interactions within 
the diagnostic mediums is not well explored. This study demonstrates an application of infrared 
(IR) spectroscopy of sera for monitoring inflammatory bowel diseases (IBD) and various cancers. 
Using samples from experimental mice and human patients, the power of IR spectroscopy in 
structural studies of proteins and other complex band contours are explored to find spectral 
signatures.  
Two experimental models of IBD; interleukin 10 knockouts (IL10-/-) and Dextran Sodium 
Sulfate (DSS) induced mouse shows diagnostic accuracy with 80-100% sensitivity and specificity 
values. Importantly, the findings of human IBD patients’ serum also show promising results 
resembling our proofs-of-concept investigations of mouse models. Maximum values of sensitivity 
and specificity are 100% and 86%, respectively, in human samples. Similarly, in cancer studies, 
the EL4 mouse model of non-Hodgkin lymphoma (NHL) and a B16 mouse model of the 
subcutaneous melanoma are used to extract a snapshot of tumor-associated alteration in the serum. 
The study of both cancer-bearing mouse models in wild types (WT) and their corresponding 
control types emphasizes the diagnostic potential of this approach as a screening technique for the 
NHL and melanoma skin cancer. The breast cancer (BC) -associated protein conformational 
alteration in the serum samples shows the sensitivity and the specificity of identifying spectral 
signatures were both 90%. All in all, IR spectroscopy of serum samples accompanied by spectral 
analysis technique shows some promising results for disease diagnostics. The brief outlook of the 
fundamentals of the infrared detection technique and their applicability for the development of 
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1 INTRODUCTION  
Spectroscopic techniques are becoming popular exploratory tools to investigate the 
interaction between matter and electromagnetic radiations[1]. The popularity is due to the 
extraordinary sensitivity of spectroscopy to understand the molecular structures depending on 
bonding between the constituent atoms and their spatial arrangements. Based on the nature of the 
measurement process, radiative energy involved in the interaction and their applications, these 
techniques are classified into several types[2]. These include classification based on atomic or 
molecular probing, electronic or magnetic features, Gamma to terahertz radiation, absorption or 
emission of radiations, and many more. The selection of an individual spectroscopic technique 
depends on the purpose of the study. Among these several spectroscopic techniques, the infrared 
spectroscopy is applicable to investigate vibrational and the rotational motions of molecular bonds 
and the spatial arrangement of the constituent atoms[3]. The usefulness of infrared spectroscopy 
arises due to the unique spectral fingerprint of each molecule type. 
In this dissertation, infrared spectroscopy is utilized to investigate the structural and 
compositional features of constituents in serum samples and disease-associated alterations within 
them. Accompanied by data analysis techniques, Fourier transforms infrared (FTIR) spectroscopy 
of sera has been explored to find disease-associated alterations in the constituent’s 
biomolecules[3]. The FTIR uses interferometry to record information about the material and these 
interferograms are being decoded into recognizable spectra via Fourier transformations. The first 
part of the dissertation investigates the feasibility of the technique to understand inflammatory 
bowel diseases (IBD) associated alteration in the serum samples of experimental mice[4-11] and 
human patients. In experimental models, acute (Dextran Sodium Sulfate induced: DSS) and 
chronic (Interleukin 10 knockouts; IL10-/-) mice are tested. Arthritis (Collagen Antibody Induced 
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Arthritis: CAIA) and metabolic syndrome (Toll-Like Receptor 5 knockouts: TLR5) models are 
also tested as controls[4, 5]. The second part of the dissertation investigates its potential to 
discriminate cancer-associated changes in the serum samples[12, 13]. In the cancer study, an EL4 
mouse model of non-Hodgkin lymphoma (NHL) and a B16 mouse model of the subcutaneous 
melanoma are used[12]. The samples of Breast cancer (BC) patients were also used to investigate 
the feasibility of the technique[13]. An outlook on the ongoing study of the standardization of 
technique for the acquisition of spectral signatures applicable in the clinical domain and preparing 
unique database is also discussed.  
1.1 Fourier Transforms Infrared (FTIR) Spectroscopy 
The interaction of light with matter depends on the nature of the material, the wavelength 
of the incident light, and the intensity[14]. Within the infrared region of the electromagnetic 
spectrum, as light interacts with matter and the chemical bonds will stretch, contract and bend. It 
is because different bonds and functional groups of constituents have a range of quantized 
vibrations and bending modes. When these constituent molecules are irradiated with infrared 
photons matching the energy of those vibrational energy levels, molecules absorb the radiation 
and start to vibrate. As a result, the amplitude of the vibration (which depends on intensity) is 
increased, but it does not affect the frequency of those vibrations and remains the same[15]. 
Therefore, a chemical functional group tends to adsorb infrared photons/radiation in a specific 
wavelength region, regardless of the structure of the rest of the molecule. The analytical technique, 
which measures the vibration characteristics (i.e. Infrared intensity versus the wavelength or 
wavenumber of light) of chemical functional groups in the sample is called infrared 
spectroscopy[3].  
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FTIR spectrometer obtains infrared spectra by first collecting an interferogram of the 
sample that measures  IR frequencies simultaneously, and digitizes it followed by performing the 
Fourier transformation[16]. It takes advantage of how IR light changes the dipole moments of 
molecules at the specific vibrational energy (𝐸 = ℎ𝜐 = ℎ 𝑐 𝜆 = ℎ𝑐?̅? ⁄ , where c is the velocity of 
light and h is Planck’s constant) corresponding to reduced mass (µ) and the bond spring constant 
(k)[17];  






                         …………. (1)  
 
 
Figure 1.1 (A) The schematic of FTIR spectroscopy. The infrared (IR) detector receives 
an interferogram, and our computer does the Fourier transformation to generate the absorbance 
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spectrum. It simultaneously collects data over a wide spectral range, reflecting how much light is 
absorbed by a sample at each wavelength. (B) Different sampling modes of FTIR spectroscopy, 
including transmission, transflection, and the attenuated total reflection (ATR). 
 
Figure 1.1 (A) shows the schematic of an FTIR spectrometer. The Michelson 
interferometer modulates the incoming optical radiation by changing the optical path difference 
between the two possible paths. Thus, formed interferograms are the coded representation of the 
target spectrum. Fourier transformation decodes the interferogram and provides the spectrum of 
the target radiation. In biochemical research, FTIR spectroscopy is a powerful analytical tool that 
can be used to provide insight into the composition, structure, and interaction of constituent 
molecules within biological solutions[18, 19]. Changes in the characteristics of biological fluids 
that often occur in disease can be detected in spectral data and have emerged as a robust tool used 
in clinical[20] and forensic[21] studies.  
An increasing number of studies have demonstrated the effectiveness and promising 
application of this technique in several applications in the broad field of biological sciences[22]. 
The frequencies and their biochemical assignments of prominent spectral bands are also 
identified[23]. Standard protocols for the measurement of diagnostic mediums using FTIR 
spectroscopy[24] and spectral analysis techniques are well established[25]. However, examining 
the differences between the FTIR spectra has proven to be challenging due to the complexity of 
the biological constituents, which have different vibrational modes[26, 27]. Therefore, in FTIR 
studies, sophisticated spectral analysis techniques are employed to overcome these inherent 
spectral interpretation challenges caused by highly overlapping absorbance peaks[26]. 
5 
A variety of choices are available for the sampling modes. The three major sampling modes 
of FTIR spectroscopy include transmission, transflection and the attenuated total reflectance 
(ATR). The spectra measured by FTIR are similar in each sampling mode, but subtle differences 
exist in the interaction between light-matter interaction. The Figure 1.1 (B) shows the schematic 
of light-matter interaction in each sampling mode; transmission, transflection, and ATR. In 
transmission and transflection sampling mode samples can be sectioned into a thin layer, allowing 
for accurate spectral data acquisition. For illustration, in transflection mode, the sample is placed 
on IR-reflecting surface and measurement are performed. In this mode, the IR/source light passes 
through the sample and will reflect back from the reflecting surface (substrate) through the 
sample[24]. In transmission mode, incident infrared beam passes through the sample (prepared in 
the form of pallet, mull films etc.) and the transmitted energy is measured to generate a spectrum. 
Similarly, in the ATR sampling mode IR beam is directed through an internal reflection element 
(IRE) of high refractive index[24].  
1.1.1  Attenuated Total Reflectance Fourier Transform Infrared (ATR-FTIR) 
Spectroscopy 
ATR-FTIR spectroscopy is an excellent analytical technique to understand the molecular 
composition of soft biological mediums and complex body fluids. It provides a complementary 
technique compared to other IR approaches [28, 29] for clinical diagnostics. Thus, it is an attractive 
technique for the rapid and reliable extraction of the molecular composition within the diagnostic 
medium[24]. Combined with appropriate data analysis, this technique has been applied in a few 
biological studies as reported in a review article[23]. In ATR-FTIR spectroscopy, light is totally 
reflected inside the prism of the high refractive index[28], and the reflected light from the sample 
(Goos-Hanchen effect)[30] creates an evanescent wave, penetrating the sample placed in contact 
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with crystal[31]. The energy of the evanescent wave first interacts with the sample medium, and 
the incident wave is entirely reflected in the system as shown in figure 1.2 (A). The output spectra 
represent a snapshot of molecular components within the sample medium. Herein, the penetration 




2⁄  depends on 
the wavelength of incident radiation (𝜆), the refractive index of the crystal (𝑛1), the angle of 
incidence (𝜃), and the refractive index of the sample (𝑛2). It is noted that the evanescent wave 
decays exponentially in relation to the distance from the interface[32], so the penetration depth is 
only a fraction of incident IR wavelength. The evanescent waves lose energy at frequencies 
identical to the sample’s absorption because soft biological materials[33], such as the serum, make 
intimate contact with the ATR element. 
 
 
Figure 1.2 Interaction of light with sample in ATR sampling mode of FTIR 
spectroscopy[11]. (A) Schematic diagram of the evanescent wave formed on the sample at the 




1.2 ATR-FTIR Spectroscopy of Serum Samples for IBD Studies  
The two primary clinically identified IBDs; Ulcerative Colitis (UC) and Crohn’s disease 
(CD), are debilitating, with a chronically inflamed gastrointestinal (GI) tract[34]. It can limit an 
active lifestyle and lead towards the life-threatening complications[34], including secondary 
infections, organ degeneration, nutritional deficiencies, and even GI cancer[35]. The incidence and 
prevalence rates[36] of these diseases with unknown etiology have been increasing globally. 
According to The Crohn’s and Colitis Foundation of America, approximately 1.6 million 
Americans suffer from IBD, with 70,000 new cases being diagnosed every year [37].  
Rapid detection and preventative interventions of these diseases enable the early 
administration of therapeutic strategies when the treatment is most effective. Simultaneous 
monitoring of mucosal healing during the treatment is also critical for IBD. Furthermore, IBDs are 
chronic inflammatory disorders that affect the GI tract and are characterized by episodes of relapse 
and remission requiring continuous monitoring. Certainly, ground-breaking advances in the 
interruption of these diseases[38] have been achieved using human and animal models of intestinal 
inflammation. However, a reliable screening test to diagnose these illnesses by primary care 
physicians, and hence the early administration of the therapeutic strategies, is not yet available[39]. 
At present, the gold standard routine tests such as colonoscopy, sigmoidoscopy and small 
bowel follow-through are recommended for colorectal and GI diseases[40], including IBDs. The 
existing guidelines recommend that individuals, fifty to eighty years of age should get a 
colonoscopy done every five years as part of a routine checkup[41]. Nonetheless, these gold-
standard tests are expensive (requiring specialized instruments and qualified personnel and prior 
preparation), invasive, risky (such as colonic perforation, hemorrhaging, post-polypectomy 
electrocoagulation syndrome and infections), unpleasant for patients, and are not easily accessible 
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to the eligible population for disease screening. These factors have become significant hindrances 
to patient adherence to regular preventative IBD disease screening and monitoring. Studies further 
show that the onset of IBD typically occurs in the second and third decades of life[42], progressing 
into episodes of relapse and remission in the GI tract. Therefore, developing an affordable, 
sensitive, specific, user-friendly, robust and rapid, equipment-free and deliverable to the end-users 
(ASSURED) prescreening test before a colonoscopy is a critical need. 
Blood and it’s component-based biomarkers[43] have been previously studied, utilizing 
gene panels to predict and discriminate IBD disease activity[44]. The blood gene expression 
analysis offers the significant potential to expand the understanding of the underlying genes’ 
involvement[44], and can play a major role in the development of personalized medicine[45]. Data 
interpretation in gene expression analysis is not straightforward and requires several steps 
appropriate to the experimental protocols[43-45]; thus, gene expression analysis is not yet able to 
provide a low cost, quick and easier early screening test, keeping the traditional means of 
evaluations (such as a colonoscopy) as the gold standard. We explore the utility of FTIR 
spectroscopy of serum samples in ATR sampling mode[24], which could, in the future, allow 
physicians to diagnose and/or monitor IBDs in its early stage. This technique is simple but 
possesses the potential for radical change from standard practices as it will lead to the development 
of a preventive screening technique before the use of invasive, risky colonoscopy. 
The loss of energy in the decaying process will be at frequencies identical to the sample’s 
absorption for soft biological materials like body fluids[33]. Similarly, metabolic discharges into 
the body fluids (saliva, excreta, blood, and other tissue fluids) from the proximate diseased tissue 
change the constituent molecules, providing strong guidance for subsequent clinical 
assessment[33, 46]. Therefore, body fluids are considered as precious and ideal diagnostic 
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mediums of clinical biomarkers owing to the advantages of minimal invasiveness, low cost, and 
rapidity of sample collection and processing. ATR-FTIR spectroscopy of body fluids has garnered 
much attention in the scientific community, including from clinicians[47, 48]. Serum is the 
protein-rich blood component extracted after the removal of cells and clotting factors from the 
whole blood sample[49] and it is used in numerous diagnostic tests[50, 51]. Thus, present infrared 
spectral studies enriched with data analysis techniques on samples of human IBD patients and 
experimental mice[4-10]can pave the way for identifying diseases in the blood. 
1.2.1 Spectroscopy of Serum Samples from Experimental Mouse Models   
Mouse models have been a vital tool for research in GI Diseases. The understanding of 
intestinal inflammation in the IBD has been immeasurably advanced using several mouse models. 
The study presented in this dissertation also demonstrates the applicability of ATR-FTIR 
spectroscopy by analyzing biochemical changes in samples of IBD mice.  
First, detailed insight into the molecular structural changes in serum samples of the DSS 
induced colitis mice[5] is presented. The DSS mouse model provides us an inexpensive, simple, 
and reproducible model to study human IBD. In addition to serum from DSS mice, this dissertation 
reports the use of serum samples of IL10-/- deficient mice. Herein, mice with IL10-/- deficiency 
treated with and without anti-TNFα antibody therapy was used to understand the efficacy of the 
technique for drug signature monitoring[6]. IBD patients tend to have a low IL10-/- producer 
genotype (a regular cytokine that plays a major role in the homeostasis of the gut) more often than 
healthy controls[52, 53]. Therefore, genetically engineered IL10-/- deficient mice were most 
frequently used as experimental models for chronic IBD studies. Longitudinal analysis of serum 
samples of IL10-/- mice using two-dimensional differential gel electrophoresis (2D-DIGE) 
proteomic analysis has shown that the accumulation of various proteins was altered under 
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inflammatory conditions[54]. Importantly, a study has shown that this mouse model develops 
spontaneous chronic IBD and are showing a promise as a model for adequately recapitulate the 
full complexity of the human disease[54]. It has been found that, human IBD is a chronic intestinal 
inflammation disorder with an unknown etiology. The genetic and epigenetic factors also play an 
important role in the onset of disease and its progression[35]. Appropriateness of IL10-/- mouse 
model to analyze the multifactorial nature of this disease including genetic factors, immune 
aspects, and the role of the microbiota contributing to IBD is also reported[55]. Therefore, the 
spectral signatures presented in this dissertation are common to both DSS and IL10-/- mouse[4-
10]. The quantified information of Lipocalin 2 (Lcn-2) levels in feces of IL10-/- mice and 
Myeloperoxidase (MPO) activity of distal colon in DSS induced colitis to monitor disease 
progression are also used to evaluate disease level on each mouse[4, 5].  
This dissertation also covers the efficacy of the FTIR technique to monitor anti-tumor 
necrosis factor-alpha (anti-TNFα) antibody therapy in IL10-/- mouse[6]. IBD patients tend to have 
an increased level of tumor necrosis factor (TNF) in serum, stool, or mucosal biopsy 
specimens[56]. TNFα is a cell-signaling protein (cytokine) that plays a central role in 
inflammation. Therefore, TNFα became a key target for antibody treatment for inflammation[55]. 
It is found that the diversity of fecal microbiota in the IBD patients shifts towards the control 
individuals[57] after anti-TNF therapy. This treatment option leads to mucosal healing, reducing 
hospitalizations, and surgeries while improving patients' quality of life[58]. Experiments on IL10-
/- deficient mouse models[59] also demonstrates the same outcomes[60]. The cytokines in the stool 
samples show, the debilitating IBD conditions of IL10-/- deficient mice can be improved by anti-
TNFα antibody therapy[61]. 
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1.2.2  Spectroscopy of Serum Samples from Ulcerative Colitis (UC) Patients 
The animal models are not enough for preclinical human disease studies and for confirming 
the potential clinical applicability in humans. Therefore, as a follow-up step, we investigate a 
diagnostic application of IR spectroscopy coupled with data analysis techniques to understand 
ulcerative colitis-induced alterations in the molecular components of serum samples extracted 
from IBD human patients. Alterations reflected as fluctuations in vibrational modes and are used 
to identify suitable spectral signatures. The findings of this study resemble the proof-of-concept 
investigation with experimental (both DSS and IL10-/-) mouse models, providing preliminary 
evidence for a reliable diagnostic test for human ulcerative colitis. 
This study enriched with data analysis techniques on human sera that resemble mouse study 
can pave the way for identifying diseases in the blood while translating findings from an animal 
study to a human study. The perspective of the technique with its appropriateness and necessary 
improvements for the development of a new diagnostic regimen for IBDs using a serum is also 
provided. 
1.3 ATR-FTIR Spectroscopy of Serum Samples for Cancer Studies 
The FTIR spectroscopy combined with appropriate data handling frameworks has been 
widely applied in many oncological studies[23] such as studies using cancerous tissues from the 
cervix[62], the lung[63], the breast[64], the skin[65], the gastro-intestine[66], the prostate[67], the 
colon[68], the ovary[69], the urinary bladder[46]. These studies have reported that the molecular 
structural rearrangement associated with cancer development alters the vibrational mode of the 
molecular functional groups of the affected tissues as manifested in spectral signatures or 
signatures. Furthermore, the ATR-FTIR[70] spectroscopy represents a complementary approach 
for the clinical applications, compared to other IR approaches[29]. In this mode, high-quality 
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results with better spectral reproducibility compared to other modes can be obtained by the use of 
fluid samples[32]. It has been noted that metabolic discharges into the body fluids from the 
cancerous tissue change the constituent molecules, providing strong guidance for subsequent 
clinical assessment[33, 46].  
1.3.1 Spectroscopy of Serum Samples from Mouse models of Lymphoma and 
Melanoma 
The incidence rates of cutaneous melanoma[71], a deadly form of skin cancer, has been 
increasing in many regions and populations over the last few decades[72]. The increase has been 
of the order of 3-7% per year among fair-skinned populations[73]. At the same time, non-
Hodgkin’s lymphoma (NHL)[74], a solid tumorous condition of the immune system with a wide 
range of histological appearance and clinical features,  accounts 4.3% of all new cancer cases in 
the United States[75]. Although significant improvement has been made to stabilize the number 
of NHL cases and to increase its five-year survival rate, the existing diagnostic techniques, which 
include the histological examination using a biopsy, are time-consuming, invasive, costly, and are 
not accessible to the entire at-risk population. Developing a rapid and reliable prescreening 
strategy for melanoma and lymphoma is thus critical because of early diagnosis and treatment of 
these malignancies better improve[76, 77] the patient’s chances of survival.  
This study presents, ATR-FTIR spectroscopy of serum samples in an effort to assess 
biochemical changes induced by non-Hodgkin’s lymphoma and subcutaneous melanoma[12]. An 
EL4 mouse model of non-Hodgkin lymphoma and a B16 mouse model of subcutaneous melanoma 
are used to extract a snapshot of tumor-associated alteration in the serum. The study of both cancer-
bearing mouse models in wild types and their corresponding control types, emphasizes the 
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diagnostic potential of this approach as a screening technique for NHL and melanoma skin 
cancer[12].  
1.3.2 Spectroscopy of Serum Samples from Breast Cancer (BC) Patients 
BC is the most common invasive cancer among women worldwide[78]. The international 
agency for research on cancer (IARC) reports that BC comprises 22.9% of invasive cancers in 
women[78, 79]. At present, personal inspection and imaging remain the preferred methods for 
screening the asymptomatic women for BC. Nonetheless, the gold standard mammography entails 
high costs, is not available in all medical centers, and has a low sensitivity in young women and 
in the dense breast. Furthermore, BC typically produces less to no symptoms when the tumor is 
small and is easily treatable[80]. Established mammography screening, may miss up to 20% of 
underlying BCs [81]. It may also lead to a 30% rate of overdiagnosis and may increase unnecessary 
surgical procedures and patient anxiety[82]. These limitations have led to the investigation of 
blood associated protein markers[83] that can be used for BC screening before mammography. 
The feasibility of markers like CA15-3, HSP90A and PAI-1 for the early prognosis[84] is still 
unclear. It is thus critical to explore potential new markers that can help for early detection of BC. 
Our study focuses on evaluating the feasibility of FTIR spectral discrimination of serum from 
healthy controls and BC patients using protein conformational alteration in serum samples via 
spectral deconvolution[13].   
Moreover, the protein regulation[85], expression[86], and profiling[87] of tissues are 
commonly used as indicators for the diagnosis, treatment, and prognosis of various stages of 
BC[88]. FTIR spectrometry has also been successfully applied to commonly used diagnostic 
material, such as blood components[88-91], breast tissue[92, 93], hair[94, 95], and other biological 
samples[96], to discriminate BC samples[89-95]. Contrastingly, the applicability of the curve 
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fitting technique while discriminating IR spectra of control and BC sera samples have not been 
well understood[97]. Spectral fitting using characteristic Gaussian Function Energy Bands 
(GFEB), improves the resolution and ease the inherent IR spectral analysis difficulties involving 
highly overlapping absorbance peaks[25]. In fact, a key element appears to be missing; the details 
of GFEB that have attributed to the specific functional groups present in sera and their BC induced 
changes.  
Additionally, body fluids, including blood-components, are considered as precious and 
ideal diagnostic mediums of clinical biomarkers[98] owing to advantages of minimal invasiveness, 
low cost, and rapidity for sample collection and their processing. The assessment of BC associated 
changes in protein secondary structures of body fluids will thus be an emerging interest over the 
existing histopathological examination of the breast biopsy materials. Alterations in the 
biochemical composition of the serum could reflect changes of physiological states due to BC, 
enabling early disease diagnosis and treatment[99].  
1.4 Protein Conformational Studies using FTIR Spectroscopy 
X-ray crystallography and nuclear magnetic resonance (NMR) have been widely used to 
examine the structure of proteins and other biological macromolecules[100]. Despite the fact they 
have been successfully used in biochemical studies over the years when it comes to the high-
resolution analysis of protein structure and function, the use of these complementary spectroscopic 
methods is hindered by the need for sampling protocols[101] and sophisticated data analysis tools. 
The X-ray diffraction technique requires a well-ordered crystal[101], while the use of NMR 
spectroscopy is limited to small proteins[102]. Data analysis protocols for these techniques are 
also complex, complicating the interpretation of the results. These limitations have led to the 
development of alternative methods for determining protein structures.   
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FTIR spectroscopy is one alternative method that can be used for protein secondary 
structure analysis [4, 103, 104]. In previous reports, the FTIR spectroscopic investigation of 
protein secondary structures[105] in BC patient serum samples was validated by several other 
analytical techniques[106] such as X-ray, NMR[107] and Circular Dichroism spectra (CD)[108]. 
FTIR technique has also been tested with various sample types and conditions, including living 
cells[109], aqueous media[110], Hydrogen deuteration[111] in serum[112], dehydration[113], and 
heat-induced[114, 115] denaturation of serum. Additionally, spectral deconvolution[108] has been 
employed to diagnose or monitor various ailments, including prostate cancer[116], lymphoma, 
melanoma, Alzheimer’s disease[117], Parkinson’s disease[118], colitis, and scrapie[119]. 
Moreover, this method has been successfully used to study protein-protein interactions[120], the 
structure of calcium-binding proteins[121], and the understanding of the uses and misuses of 
techniques[122], their optimizations,[123] and instrumental improvisations[124]. Protein 
structure, as well as protein conformational changes[125], structural dynamics, and stability, have 
also been successfully determined using the second derivative curves[126]. All in all, FTIR 
spectroscopy has emerged as a powerful tool to study protein secondary structures and can be 
clinically useful in the early diagnosis of diseases.  
In the present proof-of-concept pilot study, we have used the FTIR spectral discrimination 
using curve fitting, to obtain the best fit that reflects protein conformational changes in serum 
samples of BC patients. The curve fitting technique is also elaborated on the complex spectral 
region of carbohydrates and nucleic acids, 1000-1140 cm-1 By deconvoluting these regions of 
experimental spectra with the corresponding GFEB of various biological components, the 
differentiating signatures of controls and cancerous spectra were determined. Other IR spectral 
markers such as peak positions of the absorbance curves and spectral signatures such as the ratio 
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of absorbance values in amide II to amide III bands are also considered for discrimination. 
Statistical analysis is further performed in these identifying spectral signatures to understand 
discriminating potential. Herein, the accepted scientific premise is that the BC associated genetic 
alteration in serum is reflected in the complex region of nucleic acids including deoxyribonucleic 
acids (DNA) and ribonucleic acids (RNA). Therefore, our discussion also includes the possible 
application of genetic and proteomic molecular mapping in serum samples via FTIR spectroscopy 
for early detection of BC. We have incorporated statistical measures, holistically evaluated the 
biochemical mapping of protein structures and circulating nucleic acid components by using IR 
spectral deconvolution. A unified fitting protocol for all the samples and a potential prototype 
applicable in clinical domain is also presented. These findings go beyond the earlier study[97] 
providing spectral signatures with higher sensitivities and specificity. Similarly, the 
implementation of optimized experimental and data analysis protocols, and quantification of the 
spectral signatures by scrutinizing molecular entities rather than relying entirely on wider spectral 




Sample handling and measurement methods were carried out in accordance with relevant 
guidelines and regulations. The sera were thawed upon purchase/obtain and stored at -80oC until 
analysis. Instrumentation, measurements and analysis follow the standard protocols[24, 25]. 
Herein, the selection of instruments, their measurement parameters, spectral 
measurement/analyzing protocols, animal model selection, and human patients’ samples are 
described in stepwise.  
2.1 FTIR Spectrometer 
All the IR spectral data were obtained with the use of a Bruker Vertex-70 FTIR 
spectrometer fitted a KBr beam splitter and Deuterated Tri-Glycine Sulfate (DTGS) detector. An 
MVP-Pro ATR accessory fitted with a diamond crystal configured to have a single reflection was 
used. Medium Blackman-Harris apodization function was employed with a resolution of 4 cm-1 
and a zero-filling factor of four to provide the best resolution ability (maximum signal-to-noise 
ratio). The aperture size is also set to 2.5 mm for the optimization of the detector response without 
saturation. A Parker-Ballston gas purging system was also used to maintain purified ambient air 
in the spectrometer. 
We have performed repeated measurements and extract information from several studies, 
including references [23-25, 32], while selecting these parameters. This selection allows us to 
reduce noise, and to analyze the spectral data without losing information during spectral 
deconvolution. Resolution of 2 cm-1 gives noisy derivative spectra and of 8 cm-1 resolution gives 
rise to missing secondary structure information (spectral signatures show a lower degree of 
variability), while using a diamond ATR crystal. Therefore, a resolution of 4 cm-1 with a zero-
filling factor of 4 to give a data spacing of 1 cm-1. Diamond has a smaller acceptance angle cone, 
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which allows having a good optical design to extract good spectra. Because of the strong robust, 
and chemically inert feature of the diamond, it is considered as the best ATR crystal for routine 
measurements of biological samples[127]. Thus, optimized values of measurement parameters are 
used in this experimental and equipment setup. 
2.2 Animal Growth and Sample Collection 
2.2.1 Dextran Sodium Sulfate (DSS) Mouse 
Three-week-old female C57BL/6 wild type (WT) mice were obtained from Jackson 
Laboratories (Bar Harbor, ME). Mice were group-housed under controlled temperature (25°C) and 
photoperiod (12:12-h light–dark cycle) and fed ad libitum. Animal experiments were approved by 
the Institutional Animal Care and Use Committee of Georgia State University (Atlanta, GA), and 
performed in accordance with the guide for the Care and Use of Laboratory Animals by U.S. Public 
Health Service. All procedures were approved under the IACUC protocol #A14010. 
C57BL/6 WT mice were administered DSS (MP Biomedicals, Solon, OH) at 3% in 
drinking water ad libitum for 7 days. Feces and blood were collected on day 0 (before DSS 
treatment) and day 7. Hemolysis-free serum was collected by centrifugation using serum separator 
tubes. Mice were sacrificed by CO2 euthanasia. 
2.2.2 Interleukin 10 Knockout (IL10-/-) Mouse  
The IL10-/- mouse model develops IBD in a time-dependent manner[59]. Similarly, the 
anti-TNFα treatment on IL10-/- mice show the therapeutic efficacy in resolving intestinal 
inflammation[60]. A study indicates that IBD development and their healing is independent of sex 
(male or female) in IL10-/- mouse[61]. Similarly, Anti-TNF drugs have proven highly effective 
for targeting and diminishing the downstream effects of TNFα activation. However, the precise 
mechanism is still unclear[128]. Studies have shown that a significant proportion of patients do 
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not respond to the treatment, or they lose the effect over time. Therefore, 30-40 % of CD patients 
and 25-30 % of UC patients still need surgery at some point during their life addition to the 
biological treatment[129, 130].   
In this study, eighteen, three weeks-old female (IL10-/-) knockouts mice, obtained from 
Jackson Laboratories (Bar Harbor, ME), were used. Nine mice were treated with anti-TNFα 
therapy, twice a week by intraperitoneal injection of anti-TNF antibody, starting from the 28th day 
of their birth, and rest (n=9) are treated with Phosphate buffered saline (PBS). Feces collected on 
day 28 (4 weeks) and day 98 (14 weeks), and Lipocalin-2 (Lcn-2) was measured to assess the 
intestinal inflammation in those mice[131]. Total RNA was also extracted from colon tissues for 
further analysis.  
Similarly, blood samples collected on day 28 and day 98 was centrifuged by using serum 
separator tubes for IR spectral measurements. Herein, samples collected from mice on day 28, 
before they develop colitis constitute the control or non-colitis (n=16). The samples extracted on 
days 98 of PBS injected mice are colitis (n=9). Similarly, the samples extracted on days 98 from 
anti- TNFα injected colitis- mice are treated (n=9). All studies were performed following the 
Institutional Animal Care and Use Committee at Georgia State University (Atlanta, GA), permit 
number: A14010. 
Herein, we have analyzed microRNAs (miRNAs) to analyze the efficacy of anti-TNF 
treatment. It is noted that miRNAs are promising biomarkers for IBD[132]. We examined the 
expression levels of pro-inflammatory cytokines in the colon, to understand the response of 
therapeutics. Herein, the colonic miRNA expression analysis is performed by the quantitative 
polymerase chain reaction (qPCR) by following the protocol as discussed[132].  
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2.2.3 Collagen Antibody-Induced Arthritis Mouse  
BALB/C WT mice received collagen antibody injections (200 µL) on day 0 by an 
intravenous (tail vein) injection. (On day 6, mice received lipopolysaccharide (200 µL) by 
intraperitoneal injection in order to boost the effect). Blood samples were collected from each 
mouse on pre-treatment (day 2) and on post-treatment (day 12) from the jugular vein. Hemolysis-
free serum was collected by centrifugation of the collected blood using serum separator tubes. 
2.2.4 Toll-Like Receptor Knockout (TLR5-/-) Mouse Model of Metabolic Syndrome 
TLR5-/-) mice were grown in our facility (Dr. Merlin’s lab at the Biology department). 
TLR5-/- spontaneously develop metabolic syndrome as previously described[133]. Age-matched 
wild type (WT) and TLR5-/- mice were fasted for 5-h and baseline blood glucose levels measured 
with a blood glucose meter (Roche) using blood collected from the tail vein.  
2.2.5 Human Sera of IBD Patients   
Serum samples of IBD human patients were provided by Dr. Emilie Vienna’s from Dr. 
Didier Merlin lab at the Institute for Biomedical Sciences, GSU, Atlanta, GA 30302, USA. These 
human sera were obtained from Equitech-Bio, Inc. (Kerrville, TX, USA). Information about IBD 
patients is provided below in Appendix A.4.  
2.2.6 B16 Melanoma or EL4 Lymphoblast Tumor Model 
C57BL/6J mice (6-8 weeks, 20-22 g, the Jackson Laboratory) were engrafted with B16 
melanoma or EL4 lymphoblast via subcutaneous (s. c.) route with 2 x 105 of each cell line.  B16 
and EL4 cells were obtained from the American Type Culture Collection (ATCC) and maintained 
in DMEM with 10% FBS prior to use. Mice were euthanized after 3 weeks of tumor inoculation 
when tumors were larger than 1000 mm3 in size (see figure 1, inset (i)). Serum samples from 
tumor-bearing mice and healthy mice were isolated and stored in -80oC until analysis. All 
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experiments using animals described in this study were approved (protocol number: A17015) by 
the Institutional Animal Care and Use Committee (IACUC) of Georgia State University, Atlanta, 
GA, and experiments were conducted according to the guideline of Office of Laboratory Animal 
Welfare (OLAW), Assurance number: D16-00527(A3914-01). 
2.2.7 Human Sera of Breast Cancer (BC) Patients 
Human sera from BC patients were obtained from the Breast Satellite Tissue Bank, 
Winship Cancer Institute, Emory University, Atlanta GA, USA. The Helsinki Declaration 
guidelines were followed for sample collection, and informed consent was obtained from all 
patients. Blood was collected without additives from patients after informed consent. The blood 
was then centrifuged at ~3200g for 10 minutes, and serum was pipetted and stored at -80oC until 
analysis. The control healthy individual sera were from the baseline collection of healthy women 
(age 41-58 years) participating in an independent intervention study under approval number 13317, 
Edith Cowan University, Perth, Australia. All participants provided informed consent. The sera 
were thawed, aliquoted in small volumes, and stored at -80oC until analysis. Information about the 
BC patients is provided below in appendix.   
In this study, the serum samples from healthy controls were provided by Dr. Marlena 
Catherine Kruger at the Department of Nutritional Science, School of Food and Advanced 
Technology, College of Sciences, Massey University, Tennent Drive, Palmerston North 4442, 
New Zealand.  
2.3 Spectral Response Measurements 
The surface of ATR crystal was first cleaned with sterile phosphate-buffered saline and by 
ethanol. The cleanliness test was then conducted to ensure there are no signal peaks higher than 
the environmental noise level. Background measurement, showing the presence of any 
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environmental residue on the crystal surface or in the light path, was performed on a clean surface 
before each measurement. It allows us to get high-quality spectra using background corrections. 
Serum samples (1 µL) are deposited in order to fully cover the crystal surface and allowed to air 
dry (~10 minutes) at room temperature. An evanescent wave produced at the interface by the 
internal reflection of light interacts with the layer of the sample within the penetration depth[134] 
(see Appendix A.2 for detail). Each sample was scanned multiple times to get ten or more high-
quality (exactly overlapping) spectral data within the mid-infrared range 400 to 4000 cm-1 and 6 
reads of the 100 co-added scans for each sample (total of 600 scans) were averaged. Using OPUS 
6.5 software, all the spectra were min-max normalized by scaling the range 1800 to 900 cm-1. This 
range comprises a significant biochemical fingerprint of the biological material and the amides (I 
and II) bands[24]. Vector normalization[135] is another popular protocol where the average 
absorbance is subtracted from each data point, and the spectrum is divided by the square root of 
the sum of squares of absorbance. In general, the normalization protocol[24] can be chosen to best 
serve the purpose of comparison. In this study, min-max normalization to the amide I peak is 
employed as it emphasizes the deviation between the colitis and control sample spectra. Min-max 
normalized spectra were then sectioned within the range of 1800 to 900 cm-1 for further analysis. 
The vector normalization is also used while comparing the second derivatives spectra. 
2.4 Data Analysis 
2.4.1 Hierarchical Cluster Analysis (HCA) and Dendrogram Plot 
Our analysis includes the dendrogram of HCA, which is commonly employed to identify the 
similarities between the FTIR spectra by using the distances between frequencies and aggregation 
algorithms [63]. Using the “PAST (Paleontological STatistics[136]) 4 - the Past of the Future” 
software and the vector normalized second derivative curve of the absorbance spectra as input data 
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(variables), HCA is performed and the dendrogram is plotted. Dendrogram tree diagram 
performed, using Ward’s algorithm and Euclidian distance measurements, allow us to visualize 
the overall classification. 
2.4.2 Principal Component Analysis (PCA) 
PCA, a useful statistical analysis[137], is first performed to explain the holistic evaluation 
biomolecular content variations reflected in infrared absorbance data. Using the “PAST 
(PAleontological STatistics) 4 - the Past of the Future” software and the vector normalized second 
derivative curve of the absorbance spectra, as input data variables, we analyzed the variance-
covariance matrix with the pairwise exclusion of missing values to get the component plots. The 
scatter plot of PC1 and PC2 were used to visualize the clustering of groups together with different 
magnitudes and directions. The scree plot is also used to check the total variance presented by PC1 
and PC2 is significant. These findings from the PCA analysis led us to investigate spectral 
signatures useful in the clinical domain. 
2.4.3 Spectral Fitting (Deconvolution) for Protein Conformational Studies  
We perform quantitative analysis of the absorption band values at different spectral 
markers’ positions, which follows discrimination of secondary structures by deconvolution of the 
spectra in the amide I region. During the deconvolution process, the computed curve that best fit 
with the experimental spectrum is obtained from the superposition of Gaussian function energy 
bands (GFEB). The individual bands from deconvolution represent proteins’ secondary structures 
as discussed in the protocol papers, and similar studies in the field[108, 116-118, 120, 126] which 
were used to verify the applicability of this technique over complementary spectroscopic methods 




Figure 2.1 The process of spectral deconvolution[6]. (A) Second derivative spectra of 
amide I absorbance curve 1600-1700 cm-1.  (B) Gaussian function energy bands used to obtain a 
curve that fits the experimental absorption curve. (C) Second derivative spectra of nucleic acids 
and carbohydrates, complex band 1000-1140 cm-1. (D) Deconvolution of the complex band by 
estimating the number and position using the minima of the second derivative curve.  
 
The process of deconvolution includes sectioning of min-max normalized spectra followed 
by rubber-band correction with two baseline points, such that absorbance values at extreme ends 
of the selected region will be zero. These spectra were then fitted with GFEBs by approximating 
the position and the number of bands from the minima of second derivative spectra (Figure 2.1 
(A)) and also by the minimization of root mean square error via the Levenberg-Marquardt[138] 
algorithm. In the fitting process position, height, width, and hence integral varied such that the 
simulated curve best fits the experimental curve. Herein, the goodness of the fit is determined by 
the convergence of the root mean square error or the residual to a singular minimum value. Figure 
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2.1 (B) shows the spectral fitting within amide I. Using six bands with corresponding biological 
components; side chain, beta-sheet, alpha helix, disordered structure, and beta turns, we found that 
fitting solution is unique as determined by the second derivative. The minima (position and 
number) of the second derivatives of the spectral curves reflect the positions and the number of 
bands needed to fit the spectral curve. The minor variation of the positions of the six bands are all 
within the acceptable ranges for those biological components. Similarly, by choosing the number 
and positions of bands indicated, excellent root mean square (RMS) error values less than 0.0035 
were obtained.  It further allows us to overcome the challenges[139] of deconvolution process for 
quantitative analysis. Herein, by normalizing and sub-sectioning, the amide-I region of absorption 
spectra followed by baseline correction and spectral fitting, the effects of the bands describing 
individual biological components allow us for a more precise analysis of the spectra, thereby 
increasing confidence while comparing two states. 
Similarly, the complex region[140] of carbohydrates and nucleic acids 1140-1000 cm-1 is 
deconvoluted with six GFEB, describing individual biological components is as shown in figure 
2.1 (D).  The number and positions of GFEBs are again approximated by using the minima of 
second derivatives (figure 2.1 (C)). The sum of the integral areas covered by six bands was further 
statistically analyzed.  
2.4.4 Statistical Analysis  
Quantified values of these identifying spectral signatures are statistically analyzed to see 
the colitis-associated alteration in the blood serum, and their stabilization after biological therapy. 
Our statistical analysis mainly includes finding the sensitivity and specificity of the signatures for 
their discrimination. Sensitivity and Specificity of a diagnostic test are often used to describe the 
diagnostic accuracy/performance of the analysis in biomedical research[141]. The discriminating 
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potential of a diagnostic regimen can be quantified by the Youden index and the area under the 
receiver operating characteristic (ROC) curves [142]. The ROC curve is plotted to find the area 
under curve (AUC). The optimal cutoff value calculated based on the Youden index for each 
spectral marker is used to select the positivity/negativity of the disease and to estimate the 




The result section systematically explains the identifying spectral signatures in mouse 
models and human patients in a stepwise pattern. The quantitative information reflected in 
identifying spectral signatures; are further analyzed by using statistical analysis techniques.  
3.1 Identifying Infrared Spectral Signatures of IBD in Serum 
The serum sample extracted from the experimental models of IBD: IL10-/- and DSS mouse 
shows diagnostic accuracy with 80-100% sensitivity and specificity values. Importantly, the 
findings of human IBD patients’ study also resemble these proofs-of-concept investigations using 
mouse serum. Maximum values of sensitivity and specificity are 100% and 86%, respectively, in 
human samples. 
3.1.1 Spectral Signatures in Serum of DSS Mouse 
The encouraging results of the earlier studies using DSS mouse[4, 5] have motivated us 
further elaboration by monitoring the temporal variation of molecular composition in the serum 
along with the colitis aggravation[11]. We examined samples at days 0, 3, and 7 of the chemical 
feeding. Six mice (S1, S2, S3, S4, S5, and S6) were fed 3% DSS dissolved in drinking water. The 
serum samples were tested for the disease progression using the spectral response analysis. After 
analyzing the absorbance spectra within spectral range 1000-1140 cm-1, we learned the 
concentration of carbohydrates such as glucose and mannoses was elevated due to colitis as judged 
in previous studies[4, 5]. These studies have shown that the elevation of the spectral band 
representing the Mannose presence in the carbohydrate region. Similarly, increased presence of β-
pleated sheet protein secondary structures and decreased the presence of α-helical structures in the 
Amide I region (1600-1700 cm-1) is also evaluated.  
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Figure 3.1 (A) shows the average (n=6) of max-min normalized spectra of mice sera 
extracted from three different time periods before (days 0, 3, and 7 of chemical feedings) the DSS 
mouse model, with a Biomolecular assignment at different wavenumber regions. Our study is 
primarily focused on testing the temporal variation in serum components along with the colitis 
progression by analyzing identified unique spectral signatures of colitis (shaded regions in figure 
3.1). The second derivative curve of the absorbance spectra is shown in figure 3.1(B). Visual 
inspection of each type of spectrum shows the alteration of disease Biomarkers due to colitis. This 
variation can be seen on day 7 of DSS feeding, but not on day 3.  
 
 
Figure 3.1 (A) Averaged (n=6) ATR-FTIR spectra of serum samples derived from DSS 
mice on day 0, day 3, and day 7 of the chemical feeding. The variation in infrared absorbance on 
day 7 is higher in the complex region of carbohydrates and nucleic acids compared to on day 3. 
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(B) Second derivative curves of the absorbance spectra. Second derivative spectra show the 




Figure 3.2 Longitudinal analysis of serum samples of DSS induced colitis mice[11]. (A) 
Normalized absorbance values in the range 1000-1140 cm-1 showing changes in spectral 
signatures representing carbohydrates and nucleic acids are significant at day 7, but not at day 3. 
(B) The integral ratio of Gaussian function energy bands representing α-helix and β-sheet 
secondary structures of proteins in serum samples extracted from six mice (S1, S2, S3, S4, S5 and 
S6). The secondary structure analysis also shows the significant changes only at Day 7.  
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 Figure 3. 2 (A) shows the normalized absorbance spectra covering the complex region of 
carbohydrates and nucleic acids (1000-1140 cm-1). IR absorbance values of this region are more 
on day 7, where mice develop fully colitis. In the normalized data, absorbance values of the 
spectral position, 1076 cm-1 representing mannose, for the control (day 0) are between 0.44-0.47 
a.u., colitis (day 7) are 0.49-0.53 a.u. that the values for the intermediate (day 3) stage lies within 
the range of control. Similarly, the ratio of the integral areas taken by GFEBs representing α-helical 
and β-pleated sheet protein secondary structures for each individual mouse is shown in figure 3.2 
(B). The integral ratio of α-helix and β-sheet protein structures also show a clear difference in the 
spectral data representing day 0 with those representing day 7 of chemical administration, while 
there is no significant difference in day 3 data. In these two regions of interests (first: Glucose, 
Fructose, Mannose, and Endocyclic C-O-C vibration and second: α-helical protein secondary 
structure of amide I and β-pleated sheet structures) show alteration with higher statistical 
significance (student’s t-test, two-tailed unequal variance p-value < 0.05).  
3.1.2 Spectral Signatures in Serum of IL10-/- Mouse 
This study is the follow up for an earlier study from our lab[5]. Addition to earlier studies, 
we have increased the number of mice (samples) and therapeutic effect of anti-TNFα is also 
evaluated[6].  
Discrimination of Absorbance Values:   To monitor the therapeutic response of colitis, 
we examine the chemical composition of serum samples derived from normal (n=16), IL10-/- 
induced colitis (n=9) and with anti-TNFα therapy IL10-/- mice (n=9). Figure 3.3 (A) shows 
average representations of the normalized absorption spectra of serum samples derived from each 
mice type. Herein, we have monitored previously identified IR spectral signatures for colitis in 
diseased species with anti-TNFα antibody therapy, which displays exciting results. The alteration 
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in the IR absorption values (at identifying spectral signatures) due to colitis in IL10-/- mice come 
close to control mice in the anti-TNFα treatment treated cases.  
 
 
Figure 3.3 Normalized absorbance curve and p-value calculation results[6]. (A) Averaged 
ATR-FTIR spectra of serum samples, derived from control (Non-Colitis, n=16), treated with anti-
TNFα antibody (Treated, n=9) and colitis untreated (Colitis, n=9) mice. These spectra show 
proper anti-TNFα therapy ameliorate the colitis condition. Inset shows magnification within 1200-
1000 cm-1 and 1660-1625 cm-1, which clearly shows how the absorbance curve of anti-TNFα 
treatment comes close to the control levels. (B) P-value calculation of colitis and treated 
conditions with control types. The p-value is less than 0.05 at various spectral bands while 
comparing non-colitis and colitis, but it is always greater than 0.05 while comparing non-colitis 
and treated. The region highlighted by the pink box is the region with p ≤ 0.05.  
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The student t-test p-values on absorption spectra representing normal, colitis, and antibody-
treated colitis mice are as given in Figure 3.3 (B). It shows how absorption values vary with control 
Vs treated and the control Vs colitis within the entire wavelength region 900-1800 cm 1. 
Throughout the whole wavelength region, the differentiating signatures better than 95% (or higher) 
are highlighted by the shadowed area. These spectral regions with biomolecular assignments and 
bond vibrations having a significantly better than 0.05 are assigned as C=O of lipids (1766-1780 
cm-1), amide I of proteins (1670-1710 cm-1), amide I and amide II of proteins (1548-1649 cm-1), 
CH3/CH2 bending (1317-1383 cm
-1) and asymmetric PO2 stretching of phosphate lipids 1208-1244 
cm-1, and the mixed region of carbohydrates, and nucleic acids in 900-1159 cm-1. Due to the 
complexity of biological systems, biomolecular and bonding vibration assignments are tentative 
and are based on numerous studies as shown in table 3.1. The colitis associated changes in all these 
spectral bands come to the level of control in anti-TNFα antibody therapy mouse serum. 
 
Table 3.1 Discriminatory Infrared spectral bands of UC, with biomolecular assignments 
and their bond vibrations[6]. 
Band (cm-1) Assignment and vibrations  
900-1158 Carbohydrates[143, 144] (Glucose, Mannose, Fructose) and nucleic acids 
(Deoxyribose/Ribose DNA, RNA)[145]: C-O, C-C stretch, C-H bends, 
Endocyclic C-O-C vibration and, νs(PO2−)[146] 
1208-1244 Amide III, νas(PO2−)[147] 
1317-1382 Collagen: CH2 wagging, the vibration of α, and β anamor[148].  
1420-1430 Polysaccharides, νs (COO-), 𝛅(CH2) 
1480-1580 Amide II of proteins: (α-helical, β-pleated sheet, unordered conformation 
structures), δ(N-H), ν(C-N)[25]. 
1600-1700 Amide I of proteins: (α-helical, β-pleated sheet, β-turns, random coils, and side-
chain, β (anti-‖+turn) structures), ν(C=O), ν(C-N), CNN[25]. 
1720-1750 Lipids C=O stretching [149] 
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Identified spectral signatures: In this study, identified spectra signatures are: (a) 
absorption values at wavenumber 1033 cm-1 (I1033), primarily due to glucose presence; (b) 
absorption values at wavenumber 1076 cm-1 (I1076), representing the mannose as well as 
phosphate[23] presence; (c) the ratio of absorbance at wavenumber 1121 cm-1, associated with 
RNA presence, to its value at 1020 cm-1, associated with DNA presence (I1121/I1020); (d) the ratio 
of absorbance at wavenumber 1629 cm-1, indicating the protein presence, to 1737 cm-1 signaling 
the presence of lipids (I1629/I1737); (e) the ratio of Gaussian function energy bands representing α 
helix and β sheet protein secondary structures as obtained from the deconvolution of amide I 
region; and (f) the sum of the integral area of GFEBs used to fit the experimental curve within the 
complex band of carbohydrates, and nucleic acids 1000-1140 cm-1.  
Earlier, various serological markers were analyzed for IBD diagnosis[43] and 
discrimination of IBD types[150]. These studies have reported abnormalities in lipids, amino acids, 
and energy metabolisms in the serum samples of IBD patients[151]. Associations between fatty 
acids and inflammatory cytokines or the protein abundance and the epigenetic alteration in the 
samples of IBD patients have been also established[152].  
Similarly, proteomic analysis in serum samples of IL10-/- mice shows alterations of 
various proteins[54] under inflammatory conditions. The protein secondary structure alterations 
could be due to a melded manifestation of these protein variations. As such, variations in these 
reported serological markers are most likely the primary reason for the IBD induced changes in 




Figure 3.4 Representation of identifying spectral signatures[6]. (A) Ensemble average 
representative of absorbance at wavenumber position 1033 cm-1. (B) Ensemble average 
representative of absorbance at wavenumber position 1076 cm-1. (C) The ratio of absorption 
values at wavenumber 1121 cm-1 to 1020 cm-1. (D) The ratio of absorbance at wavenumber 1629 
cm-1 to 1737 cm-1. (E) The integral values of Gaussian function energy bands representing the α 
helical structure of protein secondary structure. (F) The integral values of Gaussian function 
energy bands representing the β pleated sheet structure of protein secondary structure. (G) The 
integral ratio of α-helix and β-sheet protein secondary structures. It shows the increased level of 
β sheet structures and a decrease in α helix structures due to colitis and their resettlement in anti- 
TNF α therapy mice. (H) The sum of the integral area of GFEBs used to fit the experimental curve 
in the complex band 1000-1140 cm-1.   
The representation of ensemble averages for identifying five spectral signatures, I1033, I1076, 
I1121/I1020, I1629/I1737, integral ratio (α/β), and the sum of the area of GFEBs used to fit 1000-1140 
cm-1 are shown in Figure 3.4. Absorption values representing the glucose peak position at 1033 
cm-1 is shown in figure 3.4 (A), and this value at the mannose peak position 1076 cm-1 is shown in 
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figure 3.4 (B). The average ratio of the RNA peak to DNA peak (I1121/I1020) is as indicated in figure 
3.4 (C), and the average ratio of the peak representing protein to lipid peak is shown in figure 3.4 
(D). Figure 3.4 (E) and figure 3.4 (F) shows the integral values of the α-helix and β-sheet protein 
secondary structures, respectively. Similarly, the average integral ratio of α-helix to the β-sheet 
structure is shown in figure 3.4 (G). The sum of integral values of Gaussian bands used to fit the 
experimental curve within 1000-1140 cm-1 are shown in figure 3.4 (H). These absorption and ratio 
values are also tabulated in Table 3.2.  
Although, the precise mechanism of anti-TNFα treatment in IL10-/- mice that helps to 
regain altered biomolecules into the control level is still unknown[128]. Specifically, proteomic 
marker (α/β) could be due to either due to anti-TNF alpha or due to the downstream expression of 
other proteins. However, our experimental demonstration verifies the efficacy of IR spectroscopy 
to monitor the signature of anti-TNFα therapy for inflammatory bowel diseases. Since the focus 
of this work is to identify the IR signatures, regaining of altered spectral signatures of IBD close 
to the control level in anti-TNFα treatment is an important finding.  
 
Table 3.2 Quantified values of identifying spectral signatures: I1033, I1076, I1121/I1020, 
I1629/I1737, integral ratio (α/β), and the sum of the integral area of GFEBs used to fit the 
experimental complex band 1000-1140 cm-1[6]. Tabulated p-values represent a comparison 













Control 0.36 ± 0.01 0.42± 0.01 1.29±0.02 31.54±0.69 4.34±0.09 13.04±0.16 
Colitis 0.41 ± 0.01 0.46± 0.01 1.19±0.01 33.85±0.69 4.40±0.06 14.17±0.12 
Treated 0.36 ± 0.01 0.42± 0.01 1.29±0.02 32.98±0.73 3.49±0.14 13.0±0.18 
P-value 1.3E-03 2.9E-03 4E-04 0.04 1.9E-05 2.1E-05 
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Statistical Analysis: The heterogeneity between each study type is further tested by using 
quantitative analysis that involves the calculation of Youden’s index, the area under the receiver 
operating characteristic (ROC) curves, sensitivity, specificity, and the calculated p-value [142]. 
Statistical measures[141] of these discrimination techniques also reveal the feasibility of the 
studied monitoring regimen in the clinical domain. The ROC curves are plotted to find the area 
under the curve (AUC); for each of these features, the threshold values were used to estimate the 
sensitivity and specificity. Then, the Youden index, (the maximum of sensitivity + specificity – 
1), was used to find the optimal cutoff values among the threshold values. Herein, figure 3.5 (A) 
shows the confirmation of the effect of anti-TNFα therapy in studying mouse groups evaluated by 
analyzing expression levels of TNFα in the total RNAs extracted from colons. ROC plots for the 
(α/β) signature are shown in figure 3.5 (B).  
 
 
Figure 3.5 (A) The expression levels of TNFα in the Total RNAs extracted from colons. 
The level of TNFα is quantified by qPCR and it confirms the effect of anti-TNFα therapy. (B) ROC 
curve for the data obtained from the ratio of the integral area of energy bands representing α-
helix and β-sheet protein secondary structures. AUC is 0.95 while comparing colitis and non-
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colitis, but its value is 0.46 while comparing non-colitis and the treated. High diagnostic accuracy 
(with AUC = 0.95) can be seen for colitis, but poor diagnostic accuracy (with AUC =0.46) for the 
treated[6].  
 
The maximum sensitivity and specificity of this particular signature were found to be 100% 
and 81%, respectively. Sensitivity and specificity are major concerns in such studies and analysis 
led to the identification of statistically significant differences in IR spectral markers between non-
colitis, IL10-/- induced colitis, and with anti-TNFα treated mice experiments. Sensitivity, 
specificity, and AUC values are calculated for all the identifying spectral signatures as shown in 
table 3.3. Statistically, significant differences can be seen between non-colitis and colitis 
conditions for identifying signatures. However, while comparing control and the treated 
conditions, approximately 50% (0.5) AUC values can be obtained, showing there is not statistically 
difference between control and treated groups.   
 
Table 3. 3 Sensitivity, specificity and AUC value calculations of identifying spectral 















Sensitivity 89 89 100 90 100 100 
Specificity 88 88 75 56 81 75 
AUC (control 
& colitis) 
0.88 0.86 0.90 0.73 0.95 0.92 
AUC (control 
and treated) 




As seen in table 3.3, AUC values while comparing control and treated are 0.54, 0.56, 0.49, 
0.66, 0.46 and 0.55 for the spectral signatures: I1033, I1076, I1121/I1020, I1629/I1737, integral ratio (α/β), 
and the integral sum, respectively. Since the AUC values of colitis and non-colitis are higher (close 
to 90%) and that of non-colitis and treated is close to 50%, showing these spectral signatures can 
be applied to drug signature monitoring. Having shown the discriminating potential of the present 
diagnostic regimen; it is essential to study many samples producing acceptable sensitivity and 
specificity values. Discriminating temporal variation during disease progression or its suppression 
is also a critical follow-up step.  
The present study provides a detailed insight into the molecular structural changes in serum 
samples of the IL10-/- IBD mouse model. Infrared spectral signatures representing proteins, 
carbohydrates, nucleic acids, and lipids are identified as the potential signatures reflecting 
molecular changes. The success of the present technique in measuring the effect of anti-TNFα on 
the identified spectral signatures will provide an additional level of information about the treatment 
option of IBD patients and will increase the possibility of adapting this technique for disease status 
monitoring. Addressing the cost and hassle of colonoscopy that discourages people from being 
screened timely, doctors, particularly primary care physicians can make their patients more aware 
of IR spectroscopic analysis of blood serum. If the test shows an indication of diseases, 
colonoscopy can be performed. However, at its present form, the molecular mapping in serum 
samples as the IR signatures of the disease cannot replace gold standard colonoscopy tests but will 
provide additional information about the IBD patients before colonoscopy. Therefore, the 
feasibility of FTIR spectroscopy to extract a snapshot of cumulative molecular interactions within 
mouse serum samples for IBD study warrant a thorough investigation, as enabled by 
interdisciplinary collaborations between spectroscopists, biologists, and clinicians.  
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Using a statistically significant number of experimental mouse models with different stages 
of disease progression and healing can establish an association between identifying spectral 
signature changes with the disease stage. Mouse model study helps us to establish an association 
between spectral signatures of IBDs with histological findings of intestinal tissues. Understanding 
the association between identifying spectral signatures and the abolition or restoration of tissue 
functions in the intestinal tract is important because lymphocytes infiltrations and erosion of crypt 
can be seen in the diseased IL10-/- mice.  
Additionally, by building a logistic regression model for the spectral features and doing 
cross-validation, a correlation between the degree of variation in spectral signatures and the level 
of Lcn-2 in their stool or myeloperoxidase (MPO) activity of the distal colon can be established. 
Research into samples of mice with intermediate stages of the disease will provide more insights 
into the evolution of healing and add confidence to the analysis and the applicability of the 
technique for early diagnostics. However, the animal models are not enough for preclinical human 
disease studies and for confirming the potential clinical effects in humans. Therefore, a follow-up 
step would be to analyze a statistically significant number of human samples to examine covariate 
effects of demographic and clinicopathological variables like age, weight, ethnicity, diet, disease 
stage, and comorbidities on the spectral signatures.  
3.1.3 Spectral Signatures in Serum of Human Colitis Patients 
Discriminate Control and UC Sera Using Absorbance values: Figure. 3.6 (A) shows a 
typical min-max normalized[24] spectrum covering the fingerprint region for biomolecules 
comprised of various biological functional groups of lipids, proteins, nucleic acids, and 
carbohydrates. The spectral difference (UC-Control), as shown in the solid green line (▬) of 
Figure. 3.6 (B), is significantly higher than the difference obtained from the multiple 
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measurements of the same sample for both Control (▬ ▬) dashed and UC (••••) dotted lines, 
almost completely overlapping). Figure. 3.6(C) shows the p-values of the Student’s two-sample t-
test (with two-tailed unequal variance) for the absorbance representing 28 healthy volunteers 
(controls) and 18 UC patients. P-values less than the nominal significance level of 0.05 indicate 
the most discriminatory features of the spectrum. P-values less than 0.025 show the validity of all 
the features, except for regions of lipid (pink line ▬ ▬).  
The prominent, discriminatory regions include C=O/C-N stretching and N-H bends in 
amides, C=O in stretching lipids, RNA/DNA nucleotides and C-O vibrations of 
carbohydrates[153]. Because of the complexity of biological systems, biomolecular and bonding 
vibration assignments are tentative and are based on numerous studies[23, 25, 147, 154-156]. The 
spectral region, 1700-1750 cm-1, is primarily recognized by its C=O stretching band in lipids[23, 
147]. The amide I (1600-1700 cm-1) vibration is known to be sensitive to the secondary structure 
of proteins[25], which mainly arises due to C=O stretching vibration with minor contributions 
from out-of-phase C-H stretching vibrations, C-C-N deformation and N-H in-plane bends. Spectral 
band around 1578 cm-1 is due to C=N adenine[147] while the region 1136-1153 cm-1 is due to the 
ring vibration mode of C-O-C including C-O-H, C-O and C-C stretch[154]. The spectral band 900-
1091 cm-1 results from C-O, C-C stretch, C-H bend, deoxyribose/ribose DNA, RNA, is(PO2−) 




Figure 3.6 Infrared absorption spectra of sera to discriminate control and UC conditions. 
(A) Ensemble average representative of min-max normalized absorbance spectra of 28 control 
serum samples (healthy volunteers) and 18 UC patients indicating biomolecular assignments. (B) 
The spectral response difference between UC and control. The average absorbance values of UC 
conditions are elevated at carbohydrate and nucleic acids regions and fluctuating up and down in 
the Amides region. The difference between repeat measurements of the same sample (Multiple 
Controls and Multiple UCs) shown by the (▬ ▬ the blue dashed and •••• the red dotted lines 
respectively) lines are negligible compared to the difference spectra between the average UC and 
average control (▬ green; UC-Control). (C) p-values of the Student’s t-test (with two-tailed 
unequal variance) for the absorbance representing healthy volunteers and UC patients. p-values 
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less than 0.05 are used to the highlight strongest discriminatory features of the spectrum. p-values 
less than 0.025 (horizontal ▬ ▬ pink-dotted line) show the validity of all the features except lipids. 
 
Studies have investigated various serological markers[43] for UC diagnosis and the 
discrimination between UC types with their clinical feasibility[150]. These studies have reported 
abnormalities in lipids, amino acids, and energy metabolisms in the serum samples of IBD 
patients[151]. Associations[152] between fatty acids and inflammatory cytokines or the protein 
abundance and the epigenetic alteration in the samples of UC patients have been established. As 
such, variations in these reported serological markers are most likely the primary reason for the 
UC induced changes in absorption frequencies of functional groups of lipids, proteins, nucleic 
acids and carbohydrates.  
Protein Secondary Structure Analysis Via Spectral Deconvolution: The amide I 
band[25], 1600-1700 cm-1, has been used for the analysis of protein secondary structures, 
especially to observe their alteration due to changes in health conditions. We have also 
implemented a spectral deconvolution technique within the amide I band to find the protein 
secondary structure alteration in sera due to UC. The spectral band 1600-1700 cm-1 is deconvoluted 
into six Gaussian band energy profiles representing the side chain (~1610 cm-1), β-sheet (~1630 
cm-1), random coil (~1645 cm-1), α-helix (~1652 cm-1), β-turn (~1682 cm-1), and β-sheet anti-
parallel (~1690 cm-1) structures. Herein, the minima of the second derivative spectra are used to 
find the position and the number of Gaussian function energy bands enough to fit the experimental 
absorption curve. The integral area covered by energy bands representing the α-helix and β-sheet 
is larger compared to other structures: side chain, antiparallel beta-sheet, disordered structure, and 
43 
beta turns.  In addition, the UC-associated alteration in the integral bands is also significantly larger 
in the α-helix and β-sheet structures, hence only these two structures will be analyzed.   
 
 
Figure 3.7 Plots of integral values of Gaussian function energy bands representing α-helix, 
β-sheet protein secondary structures in human sera. (A) Quantified integral values of α-helix 
components. (B) The integral values of β-sheet components. (C) Ensemble average representation 
of integral values of α-helix. P-values for the integral area of α-helix is 0.05 and for the mean 
position is 0.03. (D) Ensemble average representation of integral values of the β-sheet. P-values 
for the integral area of β-sheet is 9E-07 and mean position is 0.3. (E) Representation of integral 
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ratios between corresponding α-helix and β-sheet structures. Average values of control and UC 
cases for the integral ratio of α-helix to β-sheet (Integral (α/β)) shows a statistically significant 
difference with a p-value of 1E-04. (F) The ROC curve of the Integral (α/β) and the corresponding 
AUC. 
 
Figure. 3.7 shows a plot of the integral values of Gaussian energy bands representing the 
α-helix and β-sheet protein secondary structures. The integral values of the α-helix components 
are less for UC cases compared with controls (Figure. 3.7 (A)), while the integral values of the β-
sheet components are higher in UC cases compared with controls (Figure. 3.7 (B)). A significant 
difference between the integral ratios of the α-helix and β-sheet structures can be obtained between 
the control and UC groups in this study (Figure. 3.7 (C)). The mean wavenumber position, 1650.81 
± 0.07, of the energy band representing the α-helix structure has significantly moved towards the 
higher wavenumber position, 1651.05 ± 0.32 (with a p-value = 0.03), as shown in Table 3.5. 
Similarly, the integral area covered by the energy-band representing the β-sheet structures are 
different (p-value = 9E-07) between the control (19.05 ± 0.15) and UC (20.40 ± 0.17).  
Table 3.4 Quantified information about average integral values and average position of α-
helix and β-sheet secondary structure, energy bands in human serum samples. 
 
Identified Spectral Signatures: Identified spectral signatures in this study are I1033, I1076, 
I1121/I1020, I1629/I1737, and α/β secondary structure analysis. Histogram representation of ensemble 
Features Types Integral  




 ± std. error 
Significance  
(p-values) 
α-helix Control 42.74±0.25 No (> 0.05) 1650.81±0.07 Yes (< 9E-
07) UC 41.94±0.08 1651.05±0.32 
β-sheet Control 19.05±0.15 Yes (< 0.03) 1629.94±0.11 No (> 0.3) 
UC 20.40±0.17 1630.12±0.11 
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averages for four spectral signatures, I1033, I1076, I1121/I1020, and I1629/I1737, are shown in Figure. 3.8 
(A), 3.8 (B), 3.8 (C) and 3.8 (D), respectively.  
 
Figure 3.8 Histogram representation of identifying spectral signatures. (A) Ensemble 
average representative of absorbance of wavenumber position 1033 cm 1. (B) Ensemble average 
representative of absorbance of wavenumber position 1076 cm-1. (C) The ratio of absorbance 
values (I1121/I1020) at wavenumber 1121 cm
-1 to 1020 cm-1. (D) The ratio of absorbances (I1629/I1737) 
at wavenumber 1629 cm-1 to 1737 cm-1.  
 
The altered pattern between UC and control groups can be seen by comparing the range of 
data points and their average values in the identified spectral signatures as tabulated with standard 
error in the unshaded region of table 3.6. The average absorbance value of the glucose peak for 
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control and UC is 0.274±0.004 and 0.303±0.007 and the average for the mannose peak (for control 
and UC) are 0.349±0.004 and 0.373±0.006, respectively. Similarly, the average ratio of the RNA 
peak to the DNA peak is 1.510±0.011 (control) and 1.362±0.015 (UC), the average ratio of the 
peak representing protein to lipid peak is 28.804±0.642 (control) and 33.373±1.519 (UC) and the 
average integral ratio of α-helix to β-sheet structure is 2.250±0.030 (control) and 2.061±0.033 
(UC). 
Sensitivity and Specificity: The discriminating potential of any diagnostic technique is 
further evaluated by sensitivity, specificity, ROC, AUC. Figure 3.7 (F) shows the ROC curve of 
the integral ratio (α/β) and the corresponding AUC. Similarly, for each feature (Table 3.6) optimal 
cutoff values, AUC values, sensitivity and specificity were calculated with the aid of ROC curves. 
Quantified information about these features for corresponding spectral signatures are shown in the 
shaded region in Table 3.6. The maximum values of sensitivity and specificity values of each 











Table 3.5 Quantified information about identifying discriminatory bands. These include 
absorbance values at 1033 cm-1 and 1076 cm-1, the ratios of absorbance at 1121 cm-1 to 1020 cm-
1, 1629 cm-1 to 1737 cm-1. The integral ratios of Gaussian function energy bands representing α-
helix and β-sheet protein secondary structures are also discussed. Statistical measures of 
discriminatory infrared spectral signatures for UC using sera shown in the shadowed region of 
the table. The optimal cut-off and the corresponding sensitivity and specificity are calculated 
based on the Youden index. P-values are calculated based on the student’s t-test with a two-tailed 
unequal variance.   
Types I1033 I1076 I1121/I1020 I1629/I1737 Integral(α/β) 












































Cut-off value 0.273289 0.351057 1.44565 32.8145 2.09855 
AUC 0.7817 0.7619 0.9444 0.7619 0.8313 
Sensitivity (%) 89 78 100 61 78 
Specificity (%) 68 68 86 93 82 
p-value 0.001 0.003 2E-10 0.003 0.0001 
 
 
3.2 Spectral Signatures of Lymphoma and Melanoma in Serum Samples of Mouse 
Models 
Discrimination of Absorbance Values:   Figure 3.9 (a) shows the average normalized 
ATR-FTIR spectrum of air-dried serum samples extracted from tumor-bearing mouse models of 
EL4 lymphoma (n=8) and B16 melanoma (n=8) in wild types and corresponding control types 
(n=15). Using the student’s t-test, p-values (two-tailed unequal variance), the most discriminatory 
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features of the spectrum within the spectral range 1800-900 cm-1, were extracted (figure 1(b)). 
Interestingly, the features observed for different groups enable the classification between control 
cases and malignant cases and between the two malignant cases of lymphoma and melanoma. 
Molecular assignments[33, 157-161] of five spectral bands showing discrimination of EL4 
lymphoma from their control types, with higher significance (i.e. p-values < 0.05) are presented in 
Table 1. These are the bands originating from (i) amide I of protein, (ii) amide II of protein (iii) C-
H deformation of CH3/CH2 groups, (iv) asymmetric phosphate I, and (v) Carbohydrates and nucleic 
acids. Similarly, two spectral bands showing the significant difference between B16 melanoma and 
their control types are also shown in the shaded regions of the table. Significant alteration in the 
amide I band, and the complex band of carbohydrate and the nucleic acids are observed for B16 
melanoma. The difference in the p-values observed between lymphoma and melanoma could be 
attributed to the difference in mechanism of each type of tumor development, while similarity could 
be attributed to common etiology[162].  
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Figure 3.9 The discriminatory region of infrared absorbance spectra. (a) Average 
normalized ATR-FTIR spectra of serum samples extracted from EL4-lymphoma (n=8), B16-
melanoma (n=8) mouse models in wild types and corresponding control types (n=15). The inset 
(i) shows B16-melanoma mouse with tumor size approximately 1000 mm3 (day 18). An increase in 
volume of the tumor from day 9 to day 18 of tumor inoculation in B16-melanoma mouse is as in 
inset (ii). Like the B16 mouse, the elevation of tumor size is also monitored in EL4-lymphoma. The 
serum sample is extracted for both types of mice when tumor size becomes bigger than 1000 mm3. 
(b) Student’s t-test (two-tailed unequal variance) p-values of absorbance. Discriminatory region 
for lymphoma with higher significance (p< 0.05) are amide I of protein, amide II of protein, C-H 
bends of CH3/CH2 groups in α- and β- anomers, asymmetric phosphate I, and carbohydrates with 
predominant contributions nucleic acids (DNA/RNA via PO2
- stretches). Discriminatory regions 
of melanoma are amide I and carbohydrates with predominant contributions of nucleic acids[12].  
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Table 3.6 Discriminatory infrared spectral bands of lymphoma and melanoma serum 
with biomolecular assignments[12]. 
Wavenumber region 
 (cm -1) 
Assignments (taken from references[33, 157-161]) 
i 1700-1600 Amide I of proteins: (α-helical, β-pleated sheet, β-turns, random 
coils and side-chain structures), ν(C=O), ν(C-N), CNN. 
ii 1480-1580 Amide II of proteins: (α-helical, β-pleated sheet, unordered 
conformation structures), δ(N-H), ν(C-N). 
iii 1325-1380 C-H deformation: due to CH3/CH2 bending (groups in α and β 
anomers) of lipids and proteins. 
iv 1190-1240 Asymmetric phosphate I: νas(PO2
-) of lipid phosphates. 
v 1000-1140 Carbohydrates and nucleic acids: C-O, C-C stretch, C-H bends, 
deoxyribose/ribose DNA, RNA, νs(PO2
-).  
 
Protein Secondary Structure Analysis by Deconvolution of Amide I Band:  In order to 
demonstrate alterations in structural components due to malignancy, integral values of α–helical 
and β–sheet structures and their ratios were statistically analyzed. Figure 3.10 (a) and 3.10 (b) 
show the cluster plots of the integrals of α–helical and β–sheet structures respectively for the 
control, B16 and EL4 mice. These figures clearly demonstrate a separation between the 
corresponding integral values for the control and tumorous groups for β–sheet and α–helix. 
Furthermore, the ratio of integral values α–helix to β–sheet (figure 3.10 (c)) is always less than the 
control values for both mouse models with greater than 99% significance.  
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Figure 3.10 Plots of the protein secondary structures (α-helix, β-sheet) and their ratio[12]. 
(a) Quantified integral (area covered) values of α-helix components are less for tumorous cases 
compared to control. (b) Integral values of β-sheet components are higher for tumorous cases 
compared to control (c) Bar graph representation of average integral ratios between α-helix and 
β-sheet for the control, B16 and EL4. Significant alteration in integral ratio (α-helix/β-sheet) is 
found between control and tumorigenic case.  
 
Amide I and II Absorbance Values:  Amide I and Amide II are the two major bands of 
the infrared spectrum for protein interrogation in biological materials[157, 158]. The intensity and 
position of these bands, determined by backbone conformation of the hydrogen bonding pattern 
change with malignancies[62, 163]. Amide I band position shifts towards the lower wavenumber 
due to malignancy. The average position of amide I representing control is at 1641 cm-1, B16 is 
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1640 cm-1 and that of EL4 is 1638 cm-1, but the position of amide II stays the same at 1538 cm-1 
for all three types. Altered position of amide I is statistically significant for EL4 (*p = 0.001) while 
that of B16 is not significant (*p =0.2). Similarly, the altered ratio between amide I and amide II 
absorbance values are significant (*p = 0.01) for EL4 lymphoma, but not (*p = 0.3) for B16 
melanoma in comparison to the control groups.  
Nucleic Acids and Carbohydrate Analysis: In the region 1140-1000 cm-1, there are 
plenty of overlapping vibrational modes of biological macromolecules[23] with the major 
contribution of nucleic acids and carbohydrates[24]. Bands approximately at 1121 cm-1 arise from 
RNA absorbance, whereas the band at 1020 cm-1 arises from DNA absorbance[145].  The spectral 
band near 1080 cm-1 is due to νs(PO2
-), and the band approximately at 1056 cm-1 corresponding to 
the νs(PO2
-) absorbance of phosphodiesters of nucleic acids and the O-H stretching coupled with 
C-O bending of C-OH groups of carbohydrates[164]. Similarly, absorbance near 1033 cm-1 and 
1076 cm-1 are due to the presence of glucose (C-O stretching carbohydrate, β-anomer) and 
mannose (C-O stretching carbohydrate α-anomer). Alteration in the concentration of two 
sequences of basic genetic materials- (a) RNA (which play an active role in protein synthesis) and 
(b) DNA (which is primarily involved in the storage, copying and transferring genetic 
information), has been already reported from the tissue analysis of NHL[145] and subcutaneous 
melanoma[165]. Due to the fluctuation in these biomolecules, there is a dissimilarity between 
malignant groups from their control types. In order to verify these dissimilarities, we have used 
Hierarchical Cluster Analysis (HCA) along with spectral deconvolution within this spectral range.  
Dendrogram of hierarchical cluster analysis: HCA is commonly employed to identify 
the similarities between the FTIR spectra by using the distances between spectra and aggregation 
algorithms[63]. The dendrogram of HCA is performed with ATR-FTIR spectra of control, B16, 
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and EL4 mice are shown in figure 3.11. Dendrogram tree diagram performed using spectral region 
of nucleic acids and carbohydrates, 1140-1000 cm-1, using Ward’s algorithm and squared 
Euclidian distance measurements, allow us to visualize of overall grouping structure, including the 
sub-groups. The distinct cluster for the control spectra which are grouped together, describing a 
high degree of similarity within the groups. Similarly, there is a distinct clustering in the cancer 
spectra showing the higher degree of heterogeneity between spectra of cancerous groups. 
 
 
Figure 3.11 Dendrogram of hierarchical cluster analysis[12]. The dendrogram tree 
diagram performed within spectral range 1140-1000 cm-1, by using Ward’s algorithm and squared 
Euclidian distance measurements. The spectra are correctly classified. Control spectra appear 
grouped together, which describes a high degree of similarity within the groups. Similarly, there 
is a distinct clustering in the cancer spectra in two subgroups showing the higher degree of 




Figure 3.12 The integral sum of Gaussian energy profiles used to fit experimental curves 
within 1000-1140 cm-1. (a) The sum of integral values of control groups cluster within the 
approximate range 12-14, B16 covers the range 15-17 and EL4 covers 15-18. (b) Bar graph 
representation of the average value of the integral sum which shows significant differences 
between control and tumorigenic case[12]. 
  
Furthermore, to quantify tumor-associated alteration within this complex spectral region 
of 1140-1000 cm-1, deconvolution of experimental spectra into Gaussian function band profiles is 
further employed. Six Gaussian function energy band profiles (figure 5(b)) are used to fit the 
spectra by approximating number and position using the minima of second derivatives (figure 
5(a)). The sum of the integral areas covered by six bands (integral values) is then statistically 
analyzed to evaluate the tumor-associated alteration in the serum. A calibration curve is obtained, 
55 
as shown in figure 3.12(a) between control and tumorous groups. A clear separation between 
control (12-14) and cases of tumorigenicity B16 (15-17) and EL4 (15-18) is found while adding 
integral values. The bar graph representation of these values with significance greater than 99% is 
shown in figure 3.12(b).  
 
Table 3.7 Quantified values of discriminatory features. Clear separation can be seen 
between control and cancerous cases (both B16 and EL4) while comparing integral values of α-
helix, β-sheet structure components, and their ratios. Similarly, the altered position of amide I 
peak, amide I/amide II ratio and absorbance values at 1212 and 1335 cm-1 show significant 
difference only between EL4 and control. 
Feature Spectral deconvolution Amide I and II Absorbance 
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3.3 Spectral Signatures of BC in Serum of Human Patients  
Using absorbance spectral data of serum samples (using n = 10 each BC and controls), we 
investigate the applicability of FTIR spectroscopy to discriminate between the control and cancer 
sera. ATR sample mode of FTIR spectroscopy is used, and the discrimination between the control 
and test groups were done using various data analysis techniques. The investigation involves 
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multivariate analysis, p-value calculation, quantification by spectral deconvolution and is followed 
by statistical analysis. 
 
 
Figure 3.13 PCA analysis of second derivatives curves of FTIR absorbance spectra[13]. 
(A) PCA scores plots (PC1 x PC2) with 95% confidence ellipse. The data related to control groups 
(• • black dots enclosed by a black shaded ellipse) and BC (▪ ▪ red dots surrounded by a red-shaded 
ellipse) are clustered together with different magnitudes and directions. (B) Scree plot of 
eigenvalues showing the percentage variance of components one and two is significant compared 
to others.  
 
Principal Component Analysis: (PCA), a useful statistical analysis[137], is first 
performed to explain the holistic evaluation of protein structural content variations reflected in 
amides (amide I and II region, 1480-1600 cm-1). Herein, each of the ten samples is measured twice 
(measurement replicates) to obtain 20 spectral data of BC and 20 of control. Using the “PAST 
(PAleontological STatistics) 4 - the Past of the Future” software and the vector normalized second 
derivative curve of the absorbance spectra within 1480-1600 cm-1, as input data variables, we 
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analyzed the variance-covariance matrix with the pairwise exclusion of missing values to get the 
component plots. The output of the component plot with 95% ellipses is showing (Figure 3.13 (A)) 
a clear separation between each studied group. The scatter plot of PC1 (variability 88%) and PC2 
(variability 6%) shows the data related to control and BC groups are clustered together with 
different magnitudes and directions. Figure 3.13 (B) is the scree plot showing the total variance 
presented by PC1 and PC2 are significant. These findings from the PCA analysis of amide bands 
have led us to investigate spectral signatures useful in the clinical domain.  
Discrimination of Average Absorbance: The average of normalized absorbance spectra 
for both control and BC sera that includes the fingerprint region of biological functional groups 
(lipids, proteins, nucleic acids, and carbohydrates) is shown in Figure 3.14(A). Solely by looking 
at the FTIR spectra, it is difficult to discriminate between the absorbance of the functional 
components of the two groups. However, the comparison of the absorbance spectra between the 
two groups using student’s t-test (with two-tailed unequal variance) revealed the discriminating 
potential at amide regions (1541-1656 cm-1) and the mixed regions of carbohydrates and nucleic 
acids (1018-1076 cm-1), as highlighted by the red ellipses in (p <0.05) Figure 3.14 (B). The 
prominent, discriminatory regions include C=O/C-N stretching, and N-H bends in amides, 
RNA/DNA nucleotides, and C-O vibrations of carbohydrates[153], as reported in previous 
studies[89]. Previous studies using principal component analysis-linear discriminant analysis 




Figure 3.14 Identification of discriminatory bands. (A) Ensemble averages of normalized 
serum spectra derived from control, n = 10 and BC, n = 10. This wider range of spectra is 
presented to show the quality of the spectra, which overcomes the noise and atmospheric 
contamination while measuring them at resolution 4 cm-1. (B) Corresponding student t-test p-
values for the control and BC. (C) The second derivative absorbance spectra confined to the 
amide-I region, covering 1600-1700 cm-1. (D) Difference between the absorbance spectra of 
control and BC, indicating up- and down-regulation of proteins, carbohydrates, and nucleic acids 
in the serum of BC patients. Figure is taken from our own publication[13]. 
 
Molecular assignments of major spectral bands showing discrimination between control and 
BC, with higher significance (i.e., p-values < 0.05), are also presented in Table 3.8. These are the 
bands originating from amides of protein, carbohydrates, and nucleic acids. The amide vibrations 
are mainly arising from C=O stretching vibration, with minor contributions from out-of-phase C-
H stretching vibrations, C-C-N deformation, and N-H in-plane bend[25]. Similarly, the mixed 
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regions of carbohydrates and nucleic acids result from C-O/C-C stretching, C-H bends, and 
νs(PO2−)[154]. The second derivative spectra of these absorbance curves revealed that the 
absorbance at the minima positions at wavenumber 1629 cm-1 and 1652 cm-1 differ between 
healthy individuals and BC patients (Figure 3.14 (C)). Elevation of absorbance values at the energy 
band 1018-1076 cm-1 (Figure 3.14(D)) suggests differences in glycomic profiling[166] and 
circulating DNA[167] in the blood components. Circulating DNA and glycomic profiling has 
proven to be critical molecular markers[166, 167] in several tumor entities. 
 
Table 3.8 Discriminatory IR bands for BC serum samples from controls, and primary 
biomolecular assignments, giving rise to the main contributions for the absorbance. Amide 
regions and the complex region of carbohydrates and nucleic acids show the discriminating 
potential[13]. 
Wavenumber (cm-1) Biomolecular Assignments 
 1700-1600  Amide I: Sensitive to protein secondary structures of proteins, which     
arises mainly due to C=O stretching vibrations and by the C-N groups. 
 1580 -1480  Amide II: Sensitive for protein conformation, originates mainly from 
the in-plane N-H bending mode along with C-N and C-C stretching 
vibrations. 
 1140-1000  Carbohydrates: Sensitive to C-O, C-C stretch, C-H bends and  
Nucleic acids: Sensitive to deoxyribose/ribose DNA, RNA, νs(PO2
-). 
 
Discrimination of Protein Secondary Structures: Figure 3.15 (A), the average of the second 
derivative spectra at the amide I absorbance region is shown. The minima of the second derivatives 
of spectra allow us to approximate the positions and numbers of Gaussian function energy profiles 
required to fit the experimental curve. The amide I band of each spectrum was deconvoluted so 
that the baseline-corrected spectra were fitted with 6 GFEB profiles by estimating the number and 
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position of the minima of second derivatives, which was simulated (▪▪▪) to fit the experimental 
curve (—) as shown in Figure 3.15(B).  
 
Figure 3.15 Protein secondary structure analysis[13]. (A) Representative second 
derivatives of absorbance spectra at the amide-I absorbance region. (B) Deconvolution of the 
amide-I region: the baseline-corrected spectra fitted with 6 GBEF by approximating number and 
position of minima of second derivatives, which simulated fits (▪▪▪) to the experimental curve ( ̶ ). 
(C) Integral area of GBEF representing α helix and β sheet. (D) The ratio of α helix and β sheet 
energy bands, which proves an elevation of β sheet and drop off α helix structures due to 
malignancies. (E) The ratio of IR absorbance at amide II (I1556) to its value at amide III (I1295). (F) 
ROC curves for the ratio of the integral area of energy bands representing α-helix and β-sheet 
protein secondary structures and the respective absorbance at amide II and amide III. The 
maximum values of sensitivity and specificity are 90% and 90% for signature α/β, while these 
values are 100% and 80% for signature I1556/ I1295, respectively.  
 
In order to assess any alterations in structural components associated with malignancy, the 
integral values of α–helix and β–sheet structures and their ratios were analyzed. Due to the fact 
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that the intensity of the GFEB has a linear relationship with the concentration according to the 
Beer-Lambert law[168], the width of GFEB and full width half maximum (FWHM), is inversely 
related to the vibrational mode lifetime, which is a function of the ‘rigidity’ of the vibrating 
bond[103]. The interaction of the molecule with its immediate environment also affects the width 
of GFEB[169]. If a molecule transfers energy to its surroundings, the spectral peak has a broader 
line width and reduced intensity, even though the concentration of the molecule remains 
unchanged. In such cases, the integral area under the curve is a better indicator of the concentration 
than the intensity alone. Interestingly, we found that even though the levels of most structures did 
not differ between the samples from BC patients and healthy individuals, BC samples had an 
increase in β–sheet structures, while the levels of α-helix structures were decreased (Figure 3.15 
(C) and 3.15 (D)). Furthermore, the amide II region is used to report on protein unfolding based 
on the extent of hydrogen exchanged. Because of the lack of water interference amide III region 
is also considered as a promising region to analyze protein structures. Herein, we have also used a 
ratio of IR absorbance at the amide II (I1556) to its value at the amide III (I1295) for analysis of BC 
associated protein alteration. The dot plots of these amides ratios are shown in figure 3.15(E).  
ROC Curves and AUC Values: Sensitivity and specificity of a diagnostic test are often 
used to describe the diagnostic accuracy/performance of the analysis in biomedical research. The 
discriminating potential of a diagnostic regimen can be quantified by the AUC values of ROC 
curves [142]. The ROC curve is plotted to find the AUC, as in Figure 3.15(F). The optimal cutoff 
value calculated for each spectral signature is used to select the positivity/negativity of the disease 
and to estimate the sensitivity and specificity. Strong discrimination between diseased and control 
serum can be seen with 90% sensitivity and 90% specificity for signature α/β, and these values are 
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100% and 80% for I1556/ I1295, respectively. The results indicated that the spectral signatures in the 
specified bands have high diagnostic accuracy.  
 
 
Figure 3.16 Understanding protein secondary structures and physics of IR interaction. (A) 
Parallel β-pleated sheet structure of proteins. N-H groups in the backbone of one strand form 
hydrogen bonds with the C=O groups in the backbone of the adjacent strand to form a β-sheet. 
(B) Right-handed α-helix structures of proteins. The backbone N-H group donates a hydrogen 
bond to the backbone C=O group, contributing to the helical structure of the α-helix[13].  
 
As shown in Figure 3.16, the backbone N-H group donates a hydrogen bond to the 
backbone C=O group to form the helical structure of the α-helix (Figure 3.16 B). In contrast, the 
backbone N-H groups of one strand can form hydrogen bonds with the backbone C=O groups of 
the adjacent strands, resulting in β-sheet structures (Figure 3.16 A). Therefore, the cancer-
associated alterations in the integral ratio of α-helix and β-sheet protein secondary structures 
suggest that protein conformational alterations accompanying changes in their biological function 
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might be a key event during the development of cancer. Several studies have shown that proteins 
in serum change during BC[88-90, 170]. The alterations in the conformational compositions are 





















In this section, the results, possible clinical applications, optimization of the technique for 
clinical applications are discussed. This includes several projects, that have been working on 
while preparing this dissertation.   
4.1 Discussion Based on DSS Study  
This study demonstrates the application of the IR spectroscopic technique for monitoring 
colitis progression on days 0, 3, and 7 of chemical administration on DSS mouse models of colitis. 
It also reveals as a preliminary step in anticipating the validity of the test for humans and the 
development of a portable prototype which can facilitate an ASSURED, IBD screening. 
Monitoring alteration in the unique spectral markers [such as the concentration of carbohydrates 
(glucose and mannose) and the alpha-helix to beta-sheet ratio of the protein secondary structure] 
reflected in the IR spectra of serum, for colitis during disease progression and suppression will 
allow us to understand the feasibility of the presented diagnostic regimens in the clinical domain.  
Also, the DSS mouse started to behave differently at day 3 of the chemical feeding, so the present 
study using samples on days 0, 3, and 7 of chemical administration, is the foundation for further 
research with an increased number of sample size. Further work is in progress to investigate dose-
dependent aggravation, and disease progression of intermediate stages at day five and its 
suppression after twelve days, after stopping the chemical feeding. Herein, the DSS mouse model 
eliminates few challenges of the human diseases studies and allows us to conduct disease research 
on the controlled environment, but there are several other challenging aspects to translate these 
findings into humanistic studies. The change in spectral signatures along with disease progression 
and suppression needs to be confirmed with the use of samples of human patients. Thus, in our 
future work, spectral signatures will be further confirmed by using serum samples from UC 
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patients. Once the unique spectral signatures are identified and confirmed, an ASSURED portable 
prototype can be developed in which measurements and data analysis techniques can be automated 
in the software, so that a technician will be able to perform the test from depositing the specimen 
onto the sample holder to the positive or negative results with a screen touch. This rapid, simple, 
cost-effective, and the minimally invasive technique would allow the assessment of disease status 
and personalized drug management in the future health care of IBD patients.  
4.2 Discussion Based on IL10-/- Study 
The application of ATR-FTIR spectroscopy to identify the treatment effect of anti-TNFα 
in IL-10-/- genotype IBD mouse model is demonstrated. By measuring spectra of serum samples 
of untreated, anti- TNFα treated and normal mice, we have compared the statistical significance 
difference between the groups and identify the discriminatory features. Identifying IR spectral 
signatures I1033, I1076, I1121/I1020, I1629/I1737, α-helix/β-sheet, and integral sum verify antibody 
therapy markedly ameliorated the disease as judged by earlier studies[58]. These data justify more 
initial findings and support the feasibility of this regimen for drug management during its 
treatment. The study of ATR-FTIR spectroscopy of serum samples thus needs to extend with a 
statistically significant number of experimental models and human participants.  
Importantly, the standardization of technique for the acquisition of spectral signatures 
applicable in the clinical domain is explored. The improved standardization of spectral signature 
acquisition is needed to assure the potential clinical application of the technique for IBD screening. 
The standardization includes reducing the unwanted experimental and data analysis specific 
variances. Herein, using a trial-and-error based approach and the clinically relevant data sets on 
ATR-FTIR spectroscopy of serum samples, most optimized parameters were used for data taking 
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and their analysis. Diagnostic performance parameters, such as sensitivity, specificity, and AUC 
under ROC curves prove the feasibility of the studied technique.   
All in all, the present study provides evidence that ATR-FTIR spectroscopy of serum 
samples accompanied by data analysis techniques could be a tool to evaluate anti-TNFα therapy 
in IBD. The study also provides a detailed insight into technical and instrumentation for its clinical 
applications. Understanding the drug signature efficacy by using IR spectroscopy of serum 
samples further strengthens the idea of the potential applicability of the technique. It is because; 
the access to this screening technique would increase the likelihood of compliance with screening 
recommendations for those who are otherwise reluctant to undergo the existing endoscopic tests.  
4.3 Discussion Based on Colitis Human Patients Study 
Early diagnosis and treatment of IBD is crucial because of its negative effects on one’s 
overall personal well-being. Nonetheless, as for earlier diagnosis of IBD, the gold standard 
colonoscopy diagnostic tests are not easily available and/or are not attractive for all eligible 
populations. These are expensive, invasive, risky, and uncomfortable for patients[171]. Limited 
studies have reported alternative approaches[43], which could make way for potential advances in 
the medical screening of IBD[44]. However, these studies are not yet able to provide a low cost, 
quick, and easy early screening test as an alternative to colonoscopies.  
The present, minimally invasive technique identifies spectral signatures as biomarkers 
associated with the development of disease and could become applicable for UC screening. This 
present technique will not replace traditional colonoscopy techniques but will provide an earlier 
indication of disease or an additional level of information about UC patients. Importantly, it can 
be regularly performed easily at a lower cost at the physician office during annual checkups to 
monitor the health of the patient with the possibility of an early indication of UC. Molecular 
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mapping in the form of IR signatures has the potential to become a routine screening regimen for 
the continuous assessment of patients. Further evaluation and resolution of UC can be performed 
afterward using established colonoscopy tests. 
We identified I1033, I1076, I1121/I1020, I1629/I1737, and integral α/β structures as spectral 
signatures for UC, and the corresponding differences between them were statistically analyzed. 
Note that experimental mouse model studies also showed that these peaks are unique to UC when 
compared with metabolic syndrome and arthritis. The ROC curve, sensitivity, specificity, and p-
value calculations further confirm the validation of our performance testing. All these spectral 
signatures’ AUC values range from 0.76 to 0.94. These values serve as important pieces of 
evidence to demonstrate the validity of the classifier. The sensitivity and specificity pair[141] and 
the p-values of the two-sample t-test also verify that the identified signatures are valid for 
diagnostic purposes. Using this quantified information of identified spectral signatures, the 
required number of controls and UC cases applicable in medical diagnostic trials[172] can also be 
calculated. The sample size estimation for high diagnostic accuracy is discussed in Appendix A.3 
in detail.  
Overall, these results of preliminary research using human samples resemble our earlier 
findings using experimental mouse models of disease and establish this technique as a proof of 
concept for further investigation using a larger sample size followed by clinical studies. Following 
the same protocol for the sample care, spectral measurements and data analysis, calibration curve 
applicable for initial diagnosis, differentiate IBD types, the monitoring of therapeutic response, the 
prediction of relapse and the ruling out of any flare-ups can be accomplished. Our study further 
paves the way for the development of new diagnostic regimens in the physician’s office for IBD 
screening as a preventive step. This simple, risk-free, and cost-effective technique with minimal 
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sample preparation and lack of discomfort will be attractive to most of the patient population in 
the routine screening for UC and other IBDs. This technique can be carried out by primary care 
physicians, as a simple & cost-effective preliminary indicator for UC so that the GI can perform 
the colonoscopies for the final verification. 
This novel proposed technique not only has the potential as an alternative for early 
diagnosis of IBDs but also for identifying the progression status of IBDs, specifically UC and CD. 
The future work includes the exploration of spectral signatures for CD differentiation between UC 
and CD.  It is because, patients undergoing an initial evaluation for IBD will often undergo a series 
of diagnostic tests, and a large amount of clinical information obtained may make a physician 
uncertain as to whether to label the patient as having CD or UC[37]. In many cases, similar drugs 
are used to treat UC and CD, but treatment is not equally efficient and responds differently. It is 
known that UC mostly presents with rectal inflammation and continuous lesions, while CD 
presents with discontinuous inflammatory lesions and frequently involves the ileocecal area. 
Studies further show, the location of inflammation (in UC colon is the only site that is affected and 
in the CD it affects anywhere along the digestive tract), the efficacy of drug treatment, aggravation 
to the other body parts[173] are also different. One can undergo a single surgery to treat UC, 
whereas CD may need multiple surgeries. It was reported that concentrations of some chemicals 
were different in UC and CD patients[174, 175], thus differentiating IR spectral markers are 
expected. 
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4.4 Potential Prototype for the Portable Device Development 
 
Figure 4.1 Structure of the software program showing 9 subroutines to perform each 
specific task[11]. Each of these specific programming tasks was individually carried out in our 
preliminary work in order to get the conclusion. In the portable device development, all those will 
be automated into one program which will be done at a single touch command.  
 
 Our study is also directed toward designing and developing a prototype of a 
portable tool for facilitating such measurements. As the first stage of the portable device 
development, we have studied the possible use of a commercially available portable FTIR 
(Brucker ALPHA & Perkin Elmer 2) with ATR setup. The communication with the commercial 
software from the FTIR manufacturer will be critical to develop a user-friendly prototype, so 






















Figure 4.2 Flow chart for the programming to study protein secondary structures[11]. 
Only the α-helix and β-sheet ratio analysis is shown in the flow chart. Similarly, other biomarker 
analysis will also be in the program as needed to achieve the needed confidence limit.  
 
Start
calculate integral ratio R (α Helix / β












Minimum-maximum normalization within spectral range 
1000-1800 cm-1.
Select and cut amide I region 1600-1700 cm-1 for 
protein secondary structure analysis.
spectral range is then baseline corrected
2nd derivative of the experimental spectra are now 
performed simultaneously to approximate the 
number/position of Gaussian function bands required to 
fit it. 
Experimental curve is now best fit by using 5 Gaussian 
oscillators with the minimization of RMS error 
(Lavenberg MaquardtMethod).
Calculate area integral of oscillators representatives of 
side-chain, β-sheet, random coil, α-helix, and anti //-β




Figure 4.3 Schematic of measurements and data analysis tool permanently integrated into 
the anticipated modified spectroscope. "Sample Scan" tab allows users to enter the patient ID, 
select the disease followed by pressing "Start Scan" to initiate the program[11]. 
 
Fully automating the spectral measurements and analysis presented above is the second 
step to check the feasibility of the proposed portable device. Minimization of the instrumentation 
by integrating it with a simple touchscreen (e.g. Windows tablet) will make it a user-friendly 
desktop unit. Spectral measurements and data analysis procedures will be automated into a single 
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step so that a technician can deposit the sample onto the sample holder and start the measurement 
with a simple click to get the result and if needed the biochemical information.  
The software program will include 9 subroutines as shown in Figure 4.1 and each will do 
a specific task in the data extraction or analyzing stage. Reading a spectral data file from the FTIR, 
extract data for a suitable biomarker range depending on the user-selected disease, normalizing 
and baseline correction of spectral data subroutines will have simple loops, condition check, and 
basics mathematical calculations. The second derivative will be calculated by using divided 
difference formulas for discrete data. After finding the number of minimums and their positions, 
the program will assign parameters for Gaussian oscillators. The curve fitting subroutine will 
iteratively vary the Gaussian curve parameters to minimize the RMS error between the 
experimental absorption curve and the corresponding summation of the Gaussian curves. The 
Levenberg Marquardt algorithm will be used in this subroutine. The standard numerical integration 
technique will be used to find the area under each Gaussian oscillator.  
As an example, the flow chart for protein secondary structure analysis is shown in figure 
4.2. Other biomarkers already identified and new ones to be identified in the process can also be 
included in the program. For debugging and troubleshooting reasons, it is important to be able to 
see the output at each stage in addition to the outcome. Also, this allows anyone interested to see 




Figure 4.4 Anticipated portable device with the touch screen showing "Test Report". The 
test report can be printed as a hard copy or save the patient record in the hospital database[11]. 
  
A schematic of this anticipated portable prototype for the colitis screening by using ATR-
FTIR spectroscopy is shown in figure 4.3, where the microprocessor (I) controls all the functions 
in the instrument, and the software (spectral measurement and data analysis) will run on a 
microprocessor (II). The software package developed can be installed on the Windows tablet PC 
attached to the portable FTIR. Herein, the "Sample Scan" tab allows users to enter the patient ID, 
select the disease, followed by the user pressing "Start Scan" to initiate the program. Pressing 
"Start Scan" after depositing a sample on the holder can automatically perform the full data 
analysis and will display a laboratory test report as seen in figure 4.4.  
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4.5 Discussion Based on Lymphoma and Melanoma Study 
The results of the present study shown remarkable differences between the ATR-FTIR 
spectra of serum samples representing tumor-bearing mouse models of melanoma (n=8) and NHL 
(n=8) from their control (n=15) types. The differentiating signatures between spectra are obtained 
by observing (i) p-values comparison, (ii) the spectral position, and ratio analysis of amide peaks 
(iii) the fit of the experimental spectra and (iv) the employment of multivariate analysis (HCA). 
This difference between control and tumorous cases is evident through the gradual changes in the 
intensities of the absorption of mainly proteins, carbohydrates and nucleic acids in the serum. It is 
noted that serological tests show the alterations of certain proteins, peptides, and nucleic acids 
(DNA, mRNA) for patients with melanoma[176] and lymphoma[177]. Manifestations of these 
alterations in biomolecules (serological markers) are most likely due to the tumor-induced 
alterations directing towards identifying the spectral signatures. 
Herein, this is an experimental demonstration of the rapid and reliable spectroscopic 
techniques for the discrimination of B16 melanoma and EL4 lymphoma mice from their control 
types. B16 murine tumor model remains indispensable for metastasis and therapeutic studies of 
human melanoma skin cancer[178].  Similarly, development of EL4 murine tumor model 
considered a huge benefit to the human NHL research cancer. This work is thus expected to lay a 
foundation for further research which could lead to the development of diagnostic techniques for 
future health care of cancer patients of melanoma and lymphoma using body fluid samples that 
can be collected with relatively low risks. It is thus critical to extend the present study to human 
patients for the assessment of disease status and personalized drug management. Furthermore, the 
study of temporal variation in spectral marker signatures is important for tumor grading, sub-
typing, and assessing heterogeneity. Further work is in progress (i) to investigate temporal 
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variation in serum components along with the progression of the disease by increasing sample size, 
(ii) identify the alteration in spectral signatures using human patients, and (ii) to integrate data 
analyzing software into the narrow multiband detector. After setting a calibration curve of unique 
spectral signatures for NHL or subcutaneous melanoma, bulky instrumentation will be avoided 
using specific multiband IR detectors capable of simultaneous detection in the expected narrow 
bands. Recent advances in IR technology allow the operation of multiband detectors at room 
temperature[179]. Complex statistical analysis of identifying spectral signatures of NHL or 
melanoma can also be integrated into the clinical tool as a software application into the computer 
program. In terms of clinical application, we can anticipate that the potential technology can be 
further developed into a personalized diagnostic tool in which patient-to-patient and within a 
patient over time (due to health conditions or other factors) differences in molecular signatures 
would allow the assessment of disease status and personalized drug management. To be used as a 
patient to the patient screening test, a normal range of spectral signatures unique to the particular 
disease should be set by using a statistically significant set of normal serum samples. These average 
normal values can be incorporated into the program which can identify the deviations of the test 
sample from the average values. Technological advancement of ATR-FTIR spectroscopy of serum 
sample to discriminate normal and tumorous conditions will thus support to increase compliance 
rate eligible population for tumor screening and to make physician decision for advanced 
histological examination using biopsy.  
4.6 Discussion Based on BC Study 
Protein analysis is considered as a promising technique for understanding the progression 
of cancers. Similarly, FTIR spectral analysis is one of the accepted paradigms for the holistic 
evaluation of protein structural content at the molecular level in biological samples. Several studies 
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have introduced the applicability of FTIR spectroscopy in serum samples accompanied by spectral 
analysis techniques for BC discrimination. Reports[89, 97] show the potential application of FTIR 
spectroscopy for protein analysis in serum samples from the BC patients. However, cancer 
initiation, progression, and response to therapy depend on an array of complex interactions 
between constituent biomolecules (proteins, lipids, nucleic acids, and carbohydrates) and not only 
at the level of the single (biomarker or target) molecule. Therefore, the feasibility of FTIR 
spectroscopy to extract a snapshot of cumulative molecular interactions within serum samples 
warrant a thorough investigation, as enabled by interdisciplinary collaboration between 
spectroscopists, biologists, and clinicians. It is noted that the evaluation of serological biomarkers 
(CA15-3, HSP90A, and PAI-1) do not show consistent differences between BC cases and controls 
that can lead up to diagnosis [84]. Our data show alterations in biochemical, and structural, 
information of the constituent components of the sample medium. Such, holistic evaluation of 
biochemical details with the use of IR spectroscopy can thus have an immense potential for BC 
discrimination analysis in the clinical domain. 
Deconvolution of spectral range 1140-1000 cm-1: To analyze the snapshot of alterations 
reflected in our FTIR spectral data, the complex region[140] of carbohydrates and nucleic acids, 
1140-1000 cm-1, was deconvoluted. The BC-associated alterations in the DNA and RNA are 
reflected in this region. The circulating DNA and protein markers are generally evaluated to track 
the biomolecular events of cancerous patients[180]. Herein, this spectral range is deconvoluted 
with six GFEB (Figure 4.5 (A)) by approximating numbers and positions using the minima of 
second derivatives. The sum of integral areas covered by six bands (integral values) of control, 
samples range from 11.4 to 13.2, while these values in BC samples are from 13 to 14.8. This 
quantified information was further statistically analyzed (Figure 4.5(B)), and the result shows a 
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clear separation between control and BC. Similarly, figure 4.5 (C) shows the histogram of the 
average values of absorbance at wavenumber 1020 cm-1. Absorbance at this energy band is found 
to be due to the presence of circulating DNA.  
 
Figure 4.5 (A) Deconvolution of the complex band of carbohydrates and nucleic acids 
1000-1140 cm-1. The number and position of six bands used to fit the experimental curve were 
determined by using the minima of secondary curves as in amide I case. (B) Bar graph 
representation of the average value of the integral sum which shows a significant difference 
between control and BC case. (C) Bar graph of average absorbances at wavenumber position 
1020 cm-1, which is mainly due to the presence of DNA. It also shows a significant difference 
between control and BC cases[13]. 
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Potential prototype for clinical application: Moreover, a prototype for our presented 
diagnostic regimen for clinical use can be developed. Spectral measurements and data analysis 
procedures will be automated into a single step so that a technician can deposit the sample onto 
the sample holder and start to measure with a simple click to get the result and, if needed, the 
biochemical information easily as shown in Figure 4.6. ATR-FTIR spectroscopy (that is reliable 
for body-fluids analysis) integrated with two micro-controllers, where micro-controller A controls 
all the functions in the FTIR, while the controller B controls software for data analysis. The 
software program will include several subroutines as reading spectral data from the FTIR; extract 
data for suitable spectral signatures in the measured range; normalizing and baseline correction of 




Figure 4.6 Schematic of ATR-FTIR spectrometer integrated with two micro-controllers 
(micro-processors) A and B. The controller A extracts the information about the signal-sample 




The second derivative will be calculated by using divided difference formulas for discrete 
data. After finding various minimums and their positions, the program will assign parameters for 
Gaussian energy bands and select settings for bands to minimize RMS error (Levenberg Marquardt 
algorithm) between experimental data and fitted curves. The standard numerical integration 
technique will be used to find the area under Gaussian bands and the ratio. Additionally, combining 
all identified multiple spectral signatures into a single diagnostic index using them as the 
discriminating signature marker, a portable device integrated with the user-friendly desktop unit 
(can automatically perform the full data analysis and will display laboratory test report) can be 
prepared.  
All in all, FTIR spectroscopy of serum samples could be a promising technique for an 
ASSURED regimen for evaluation of BC associated molecular level of alteration in constituent 
protein structures. Our study holds value as available techniques such as mammograms, MRI, and 
ultrasonography have their limits and may not be 100% accurate[81, 181-183]. Among them, MRI 
achieves a high sensitivity of 70%–100% in the initial screening (prevalence), compared at 40% 
or less for mammography in patients with high risk to develop BC[182, 183], but the specificity 
of MRI is hampered by its difficulty while distinguishing the overlapping features of benign and 
malignant lesions, leading to higher false-positive rates[181]. Ultrasonography also fails to detect 
micro-calcifications and has poor specificity. Therefore, the present diagnostic regimen of BC 
having the potential to promote timely onward referral of patients for further testing and detection 
of recurrent disease, “enabling serial sample and testing with less cost, resource and radiation 
exposure” could be beneficial for several patients.  
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5 CONCLUSION 
The findings presented in this dissertation confirm the potential application of FTIR 
spectroscopy of serum samples, accompanied by data analysis techniques, promise for use as a 
clinical tool to differentiate IBD and cancer patients from healthy individuals. Importantly, it is 
evident through the use of experimental mouse models and human patients. However, the utility 
of this technique as a clinical tool requires further investigation and validations. Therefore, 
prospective studies evaluating specificity, sensitivity and accuracy of the technique on a large and 
carefully case-defined population is warranted. Accurate and objective classification, staging and 
grading for cancer management as opposed to the present gold standard, histopathological 
diagnosis, to guide treatments and predict patient prognosis is crucial to accelerate point-of-care 
decisions and potentially revolutionize cancer diagnostics in personalized medicine by using FTR 
spectroscopy.  
In the IBD study, the experimental models: IL10-/- and DSS shows diagnostic accuracy 
with 80-100% sensitivity and specificity values. In human serum samples, our study shows 
sensitivity and specificity values are 100% and 86%, respectively. Similarly, in cancer studies, 
mouse models of NHL and subcutaneous melanoma, emphasizes the diagnostic potential of this 
approach as a screening technique. Similarly, the BC-associated protein conformational alteration 
in the serum samples shows the sensitivity and the specificity of identifying spectral signatures 
were both 90%. Various spectral signatures were analyzed as shown in Table 5.1. These include 
(a) absorption values at wavenumber 1033 cm-1, (b) absorption values at wavenumber 1076 cm-1; 
(c) the ratio of absorbance at wavenumber 1121 cm-1, to its value at 1020 cm-1, (d) the ratio of 
absorbance at wavenumber 1629 cm-1, to 1737 cm-1. (e) the ratio of GFEB representing α helix 
and β sheet protein secondary structures as obtained from the deconvolution of amide I region, (f) 
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the sum of the integral area of GFEBs used to fit the experimental curve within the complex band 
of carbohydrates, and nucleic acids 1000-1140 cm-1 (g) absorbance at wavenumber 1212 cm-1, and 
the absorbance at wavenumber 1335 cm-1.  
 










Studied types Discrimination from the controls 















DSS Colitis Yes Yes Yes Yes Yes …. ….. …. ….. ….. 
IL10-/-  
Colitis Yes Yes Yes Yes Yes Yes … …. …. …. 
Treated No No No No No No …. …. …. …. 
Control No No No No No No ….. …. …. …. 
Human Control No No No No No …. …. ….. …. …. 
Human UC Yes Yes Yes Yes Yes …. …. ….. …. …. 
Lymphoma …. …. ….. …. Yes Yes Yes ….. Yes Yes 
Melanoma …. …. ….. ….. Yes Yes No ….. No No 
Control mice …. …. …. …. No No No …. No No 
BC Yes Yes … …. Yes Yes …. Yes …. …. 
Human Control No No …. … No No …. No …. …. 
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In this appendix, additional information on sample, study protocol and the discussion on 
feasibility of technique in clinical domain is provided.   
Appendix A.1 Understanding the Clinical Feasibility of Technique for Disease 
Screening 
ATR-FTIR spectroscopy has proven to be an excellent alternative for observing the bio-
molecular composition of body-fluids and their variations due to a myriad of pathologies[28]. 
Various studies have demonstrated the potential application of this technique in the forensic 
sciences for the routine confirmatory screening of biological evidence[48]. Consequently, several 
challenging aspects of the clinical applications of this technique have also been reported[184, 185]; 
thus, it is critical to have an in-depth understanding of these obstacles while developing a new 
diagnostic regimen.  
One of the most prevalent issues in the clinical application[185] of this technique is the 
variation in the localized drying of the serum sample[184]. To address this, we have 
experimentally demonstrated the effect of the “Air Drying of Serum Samples” as in Figure A1. 
Major clinical feasibility parameters such as “Measurement to measurement” and “User to user 
reproducibility” during the spectral measurements are further tested and outlined in Figure A2. 
These studies show that the effect of localized drying phenomena of the sample on the ATR crystal 
surface is negligible compared to disease-associated changes as reported elsewhere. Note that the 
disease-associated alteration in the spectral data can be further optimized through the use of 
spectral classification techniques[186].  
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Furthermore, the user-friendly instrumentation, integrated with intelligent software 
packages for presenting the diagnostic regimen, is necessary for the acceptance of the technique 
as a possible technological development. A schematic of our instrumentation, accompanied with 
our standard spectral analysis process of chain functionality, data records, averages, 
normalizations, deconvolutions, and quantifications are briefly presented in our earlier study.  
Air drying of serum samples: The drying phenomena of liquid droplets deposited on a 
solid surface depends on various, complex physical mechanisms, including fluid dynamics, 
properties of the liquid and contact surface, and heat transfer[184]. In the ATR sampling mode, 
the drying of serum samples results in complicated patterns[185]. We have tested the drying 
phenomena of the serum sample and their overall impact while comparing the composition within 
the control and colitis samples as shown in Figure. A1. The serum sample deposited on the surface 
was allowed to air dry at room temperature. Images (A-H) in Figure. A1 show the serum sample 
throughout the drying process continues.  
Figure. A1 (A) is the image after 4 minutes of its deposition, and the following images (B-
H) are at additional two-minute intervals. Figure. A1(I) shows the spectral data and their variation 
with the sample crystallization: Spectra 1 represents the first spectra measured after 4 minutes of 
sample deposition, 2 indicates the second spectra and 3 denote the third spectra. After 10 minutes 
of sampling and 5 spectral scans, the absorption curve displays promising overlap. The inset I(i) 
is the magnified view of the spectral range 3225-3350 cm-1, which is mainly comprised of water 
content and proteins. Similarly, inset I(ii) is the magnified view of spectral range 1610-1670 cm-1, 
a fraction of amide I region. The red dotted spectra show measurements before the sample has 
stabilized, while solid blue lines are these spectra after the sample becomes stable. These spectral 
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data and images clearly depict that the sample becomes stable on the crystal surface after 
approximately 10 minutes. 
 
 
Figure A1 (A-H) Microscopic images of one microliter serum sample during different 
stages of drying at room temperature. Pictures (A) to (H) indicate the image of the serum in 2-
minute intervals starting with (A) 4 minutes after its deposition and (H) 18 minutes after 
deposition. (I) FTIR spectra showing variation in absorbance during the air-drying of the serum 
samples. Spectra representing 1 is the first spectra taken after 4 minutes of sample deposition, 2 
is second spectra (~ 5.2 minutes), 3 is third spectra (~ 6.4 minutes). Overlapping spectra (solid 
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blue ▬) indicate the stabilization of the sample. Inset I(i) and I(ii) show the magnified view of 
spectral range 3225-3350 cm-1 and 1610-1670 cm-1 to highlight spectral reproducibility nearly 
after 10 minutes of sample deposition.  
 
Measurement-to-measurement and user-to-user reproducibility: We have further tested the 
measurement-to-measurement and user-to-user reproducibility as an important clinical feasibility 
parameter. Three researchers took sampling and spectral measurements to test user-to-user 
consistency. Likewise, the spectral measurements of twelve control and twelve diseased samples 
were taken to observe measurement-to-measurement reproducibility. Figure. A2(A) shows the p-
value calculations, using the student’s t-test (two-tailed, unequal variance) of the serum spectra, 
measured at two different times (the First and Second sets). Twelve measurements were taken 
using both the same sample and protocol.  These results did not indicate any statistically significant 
wavenumber position differences from different measurements. Additionally, three different 
researchers (1st, 2nd, and 3rd) took 12 individual measurements and found the P-values as seen in 
Figure. A2(B). Similarly, we no statistically significant differences between spectral 
measurements were found. These results suggest that the ATR-FTIR technique of serum 
sampling/measuring offers a viable measurement-to-measurement reproducibility with minimal 
user-to-user variations. In conclusion, these results suggest that, despite the complicated drying 
phenomena of the serum samples, the measurement-to-measurement or user-to-user variation is 
negligible compared to the difference between control and disease samples. Hence, the overall 
spectral measurements affirm the technique as it verifies the clear similarity among the same types 
of samples while discriminating between colitis and control samples.  
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Figure A2 (A) Spectral discrimination by student’s t-test (with two-tailed unequal 
variance) p-values of normalized absorbance using 12 measurements of the same sample at two 
different times. P-values >> 0.05 clearly show the similarity between these spectra verifying better 
measurement-to-measurement reproducibility of the technique. (B) P-values calculated for the 
absorbance data measured by three different researchers. Significantly, similar p-values (p⩾ 0.18 
>> 0.05) are found while comparing data from individual researchers, verifying the user-to-user 
consistency.  
 
Appendix A.2 Penetration depth of infrared light in the sera 
In ATR-FTIR spectroscopy[28], the light is totally reflected inside the prism of the higher 
refractive index with an evanescent wave from the reflected light penetrating into the serum 
sample[30]. The penetration depth of evanescent waves on the sample medium is given by the 
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2⁄ , which depends on the wavelength of incident 
radiation (𝜆), the refractive index of crystal (µ1), the angle of incidence (𝜃), and the refractive 
index of the sample (µ2). The energy of the evanescent wave is absorbed by the sample and the 
reflected light is then coupled back into the system as shown in Figure. A3(A). The output spectra 
represent a snapshot of the molecular component within the sample medium.    
 
 
Figure A3 (A) Light-sample interaction and formation of evanescent wave in ATR 
sampling mode.  (B) Output spectra of 1𝛍l of serum samples using diamond and Silicon crystals.  
   
Specifically, for serum samples, penetration of around 2 𝛍m can be achieved using 
diamond crystals and with an angle of incidence equals to 45 degrees. Fig. S3(B) shows two output 
spectra of 1 𝛍l of the same serum sample using two different ATR crystals, Diamond and Silicon. 
These changes are due to the difference in the refractive indices of the materials of the two crystals. 
Spectra obtained with the use of the diamond crystal in the mid-infrared region is best for clinical 
application when compared with Silicon. 
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Appendix A.3 Sample Size Estimation for Diagnostic Accuracy in Human IBD Samples 
Using 18 UC and 28 Control human samples, the sensitivity and specificity values are 78% 
and 82% for identifying spectral signature, ratio (α-helix/β-sheet). These indicate that the spectral 
band ratio (α-helix/β-sheet) has high diagnostic accuracy in detecting colitis and is thus a good 
signature while developing screening tool of colitis. We have compared different sample sizes by 
using the power analysis and simulation study that is common in medical diagnostic trials[172]. At 
a significance level α= 0.05 and power levels (1-β) = 0.90, the required sample size is 70 each 
from control and disease groups (see table A1 as extracted from[172] and the initial values based 
on asymptotic theory[187]) to achieve the continuous-scale spectral signatures to  have specificity 
82% and sensitivity 90%. These 70 diseased samples can be divided into 18 initial stages, 18 
aggravated stages, 17 treatment phases and 17 healing phases. In the table, false positive fraction 
(FPF) and true positive fraction (TPF) are used to find number of samples size.  
 
Table A1 Estimated human sample sizes for continuous test using ROC (FPF0) as the basis 
for inference with α = 0.05 and β = 0.10. Simulation studies were based on the binormal ROC 




.70 .80 .90 
0.10,0.60 49 20 1 
0.20, 0.70  44 0 
 
 
Appendix A.4 Quantified Values at Spectral Signatures of UC Patients 
Table A2 Quantified values of spectral signatures of UC patients. Shaded region of the 
table highlights the data extracted from male patients and unshaded are from female. Variability 
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of these signatures (I1033, I1076, I1121/I1020, I1629/I1737 and α/β) does not show age, gender, height, 
weight, smoking and alcohol consumptions dependence in the uniform pattern, so a concluding 
remark cannot be made. 
Gender Age  Height 
(inch) 





Male 34 72 254 34.4 N Y 0.2746 0.3518 1.4189 29.1055 1.9261 
Male 41 72 240 32.5 N Y 0.3252 0.3908 1.3069 37.5426 2.0303 
Male 49 71 185 25.8 Y Y 0.2741 0.3472 1.4072 32.7251 2.2569 
Male 55 70 224 32.1 N Y 0.3263 0.4058 1.3965 34.7197 1.9682 
Male 63 69 166 24.5 N N 0.2985 0.3715 1.3650 36.6690 2.0693 
Male 71 68 189 28.7 Y Y 0.2746 0.3537 1.4459 22.2489 2.4699 
Female 21 65 136 22.6 Y N 0.3583 0.4158 1.2559 33.7787 1.9947 
Female 27 66 185 29.9 Y Y 0.2769 0.3422 1.3803 36.8969 2.1782 
Female 46 66 145 23.4 Y Y 0.2856 0.3599 1.4062 29.5883 2.0761 
Female 47 64 155 26.6 Y Y 0.3103 0.3809 1.3763 33.0132 1.9962 
Female 55 66 135 21.8 N Y 0.2574 0.3288 1.4442 34.8734 2.0969 
Female 59 64 170 30.1 Y Y 0.3212 0.3953 1.3565 49.4526 1.9258 
Female 60 66 205 33.1 Y Y 0.2825 0.3603 1.4154 21.6636 2.0273 
Female 63 67 187 31.1 N N 0.2646 0.3409 1.4372 27.4452 1.8955 
Female 65 65 163 27.1 N Y 0.3276 0.3944 1.3203 46.3393 2.1512 
Female 65 62 256 46.8 N Y 0.2896 0.3639 1.3665 31.1652 1.9071 
Female 82 66 200 32.3 N Y 0.3225 0.3974 1.2887 30.2302 2.0975 
Female 91 66 130 21 Y N 0.3753 0.4161 1.1647 34.8415 2.0337 
 
 
The quantified values of identifying spectral signatures; I1033, I1076, I1121/I1020, I1629/I1737 and 
α/β of UC patients are shown in Table A2. These data do not depend on the age, gender, height, 
weight, smoking and alcohol consumptions of UC patients. However, while comparing with the 
corresponding values with control samples tabulated (Table A3), statistically significance 
difference can be seen, as discussed in the manuscript. These results show the identifying 
signatures are due to UC.  
Table A3 Quantified values of control samples at spectral marker signatures. Shaded 
region of the table highlights the data extracted from male and unshaded are from female controls. 
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Variability of these signatures (I1033, I1076, I1121/I1020, I1629/I1737 and α/β) does not show age and 
gender dependence. 
Gender Age (year) I1033 I1076 I1121/I1020 I1629/I1737 α/β 
Male 34 0.2439 0.3309 1.8472 32.5201 2.2639 
Male 36 0.2724 0.3490 1.5322 20.6883 2.3639 
Male 41 0.2986 0.3699 1.4209 31.1015 2.1678 
Male 46 0.2516 0.3299 1.5741 28.0227 2.0996 
Male 49 0.2687 0.3574 1.6699 24.1412 2.5469 
Male 55 0.2698 0.3425 1.4936 30.7681 2.3792 
Male 63 0.2994 0.3704 1.4425 31.7300 2.2136 
Male 66 0.2567 0.3271 1.5818 31.9618 2.0859 
Male 66 0.3056 0.3897 1.4194 24.839 2.4585 
Male 68 0.2553 0.3282 1.5749 35.4579 2.1917 
Male 71 0.2612 0.3346 1.4868 30.8804 1.9729 
Female 21 0.3140 0.3897 1.3609 31.5131 2.2088 
Female 27 0.2634 0.3419 1.4890 23.4095 2.1454 
Female 35 0.2459 0.3314 1.5689 20.2486 2.4533 
Female 46 0.2699 0.3459 1.5567 32.7598 2.2022 
Female 47 0.2544 0.3302 1.4495 25.5301 2.1306 
Female 49 0.2592 0.3249 1.5289 33.3139 2.0304 
Female 53 0.2719 0.3613 1.6523 28.2439 2.4533 
Female 53 0.2587 0.3249 1.5686 29.2131 1.9885 
Female 54 0.2637 0.3283 1.5082 30.2426 2.0919 
Female 55 0.2814 0.3503 1.5092 32.0153 2.2074 
Female 56 0.3256 0.3883 1.2883 26.2872 2.2108 
Female 57 0.2645 0.3363 1.5441 24.9430 2.2771 
Female 58 0.2693 0.3432 1.4839 27.8657 2.4098 
Female 58 0.2757 0.3474 1.4383 34.5593 2.3635 
Female 59 0.2615 0.3389 1.4205 27.5615 2.3013 
Female 60 0.3000 0.3776 1.4245 28.6436 2.2799 








In this appendix additional information about the cancer study are presented.  
Appendix B.1 Information for BC Patients 
Table A4 Information about the BC patients: Biopsy results such as Invasive lobular 
carcinoma (ILC), Invasive ductal carcinoma (IDC), Ductal Carcinoma In-Situ (DCIS) confirmed 
the BC diagnoses. The tumor grading assessment was performed based on the national cancer 
institute (NCI) guidelines. Grade-2 denotes the intermediate grade or moderately differentiated 
tumor, whereas grade-3 denotes a high grade or poorly differentiated tumor. 
ID 1 2 3 4 5 6 7 8 9 10 
Age 
years 
41.95 56.55 65.36 46.98 50.39 37.86 58.24 30.97 65.97 63.75 











































History No Yes No No No No Yes No No Yes 
Tumor 
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2.5 cm 6.6 x 
3.9 x 
4.2 cm 
5 cm 2.4 x 
2.1 cm 





Right Right Left Right Right Left Left Right Left Left 
Biopsy 
Results 
ILC IDC IDC IDC IDC IDC IDC IDC IDC IDC 
Malignant 
Grade 
2 3 3 3 3 3 3 3 2 3 
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Nodes 











































Table A4. shows the BC patients’ clinical information. The age of BC patients ranges from 
30 years to 65 years and the age of control volunteers lies within this interval (41 to 58 years). The 
median age for BC patients and control volunteers remains similar; 53 years for BC and 52 years 
for controls. All BC patients were triple-negative (the hormone receptor subtype; estrange receptor 
(ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2/neu) 




















This appendix provides the details of the study protocol.  
Appendix C.1 Research Protocol 
Sample handling, measurement, data analysis was carried out in accordance with 
(university research) relevant guidelines and regulations. These regulations and the 
appropriateness of all the selected parameters are step wise discussed as the laboratory protocols 
while performing ATR-FTIR spectroscopy of serum samples for disease diagnostics. The 
corresponding original files are in the subfolder of L-drive (L:\HemendraThesisMaterial\ ATR-
FTIR study of serum samples). 
Spectrometer and parameter setting 
1) Spectrometer: The Bruker Vertex-70 FTIR spectrometer, with a KBr beam splitter 
and Deuterated Tri-Glycine Sulfate (DTGS) detector, was used[3]. Here, the optimization of the 
application requires the selection of various components such as: source (Hg light), optics, 
electronics, beam splitter, and detector. The beam splitter transmits half of the radiation striking it 
and reflects the other half and KBr is the most widely used material for the IR beam splitters with 
coverage of 4000 – 400 cm-1 mid-IR spectral region. DTGS detector is a sensitive room-
temperature detector for mid-IR measurements. It uses temperature-sensitive ferroelectric crystals 
of deuterated triglycine sulfate. The working principle of DTGS detector involves, as the 
temperature and hence polarizability of the crystal’s changes (due to the absorption of IR radiation) 
a charge is generated which is detected by two parallel electrodes. The deuterated form of the 
crystals is used because they have a higher Curie point.  
2) ATR accessory:  The MVP-Pro ATR accessory fitted with a diamond crystal (1 
mm x 1.5 mm) configured to have a single reflection is used to provide high levels of output. 
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Diamond has a smaller acceptance angle cone, which allows having a good optical design to extract 
good spectra. Because of the strong, robust, and chemically inert feature of diamond, it is 
considered as the best ATR crystal for routine measurements on biological samples[127]. 
Germanium ATR crystal allows higher spatial resolutions (at high magnification) because of its 
higher refractive index (µ = 4), but the use of high-magnification mode lowers the signal to noise 
ratio (SNR). Therefore, the germanium ATR crystal has not yet been used for the study of 
biological mediums[188]. Silicon ATR crystals are also not favored due to lattice vibrations within 
a biologically relevant region obscuring information below 1500 cm-1 wavenumber[189]. 
Conventional ATR crystals such as ZnS are not considered suitable for analyzing kidney excretes 
of patients with acid-base imbalance[190].  
3) Apodization: It is an optical filtering technique and is widely used in recent 
cameras as well. As in the cameras, we can set apodization in our spectroscope. Please be sure that 
the application which helps us blur background and highlight only the object to be imaged (person 
who will be in photo) is apodization. It removes the airy disks caused by diffraction around the 
intensity peak and improves the focus. Herein, appodization is used to smooth the discontinuities 
at the end of recorded time. Medium Blackman-Harris 3-Term apodization function is employed 
to reduce noise without compromising resolution.  
4) Resolution and zero-filling factor: It is the ability to separate two spectral lines 
that are very close in wavelength and it determines the maximum number of spectral peaks that 
our spectrometer can resolve. FTIR spectrometer provides different options to change resolution, 
and the change in resolution sets the change in travel distance of moving mirror. In the present 
study, A resolution of 4 cm-1 and a zero-filling factor of 4 to provide the best resolution ability 
(maximum signal-to-noise ratio). The 4 cm-1 resolution in the spectral data of range 400-4000 cm-
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1 means the system would be able to be resolving a maximum of 900 (4000-400=3600/4) individual 
wavenumbers across the spectrum. By doing so, we can get the protein secondary structure 
information and other spectral signatures appropriately. With a resolution of 8 cm-1, it is found that 
this is not appropriate for secondary structural study, as second derivative spectra do not reflect 
the accurate position of disordered protein structures. By reviewing earlier studies, performing 
multiple studies, and acknowledging reviewers’ recommendations we have used resolution of 4 
cm-1 and a zero-filling factor of 4, so that the spacing between each data point is 1 cm-1. We have 
performed repeated measurements and extract information from several studies, including 
references [23-25, 32], while selecting these parameters. This selection allows us to reduce noise, 
and to analyze the spectral data without losing information during spectral deconvolution. 
Resolution of 2 cm-1 gives noisy derivative spectra and of 8 cm-1 resolution gives rise to missing 
secondary structure information (spectral signatures show a lower degree of variability), while 
using diamond ATR crystal configured to have a single reflection of incident IR radiation. 
Therefore, a resolution of 4 cm-1 with a zero-filling factor of 4 to give a data spacing of 1 cm-1 is 
used.  
5) Zero-filling factor: The zero-filling factor decreases the spacing between the data 
points as obtained from the resolution. Simply saying it increases the array-size of the spectral 
data. The zero-filling factor should follow (2n, n = 1, 2, 3,...).  
6) Aperture size: Aperture size is set to 2.5 mm for the detector response without 
saturation. Detector saturation needs to be avoided, otherwise it will lead to “starvation”, causing 
it to generate constant signals.  
7) Gas purging system: A Parker-Ballston gas purging system was also used to 
maintain purified ambient air in the spectrometer.  
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Sample Management 
1) While handling the biological samples in the laboratory, adherence to the university 
guidelines will be absolutely required (Research Information - Georgia State Ahead (gsu.edu)). 
The exact date/time to pick the sample from the collaborator or suppliers (companies) should be 
scheduled earlier. The samples are stored in the freezer (at NSC room, Room Number 231) at a 
temperature -80oC upon received. 
2) The availability of instruments, storage, and others is also checked before 
scheduling meetings with collaborators or before buying samples or performing the measurements. 
Necessary information was collected about the samples ahead so that we can set the measurement 
parameters accordingly and continue measurement immediately. 
3) Samples were received in the labeled transparent storage containers kept 
systematically in a paper box, plastic, or dried ice containers depending on the nature of the sample. 
The storage condition is also checked with a colleague or with company representatives who had 
collected these samples, before the measurement. 
4) Currently, the freezer at room 232 NSC (Dr. Hasting’s lab) is used to store samples. 
Container tubes that are put in one column of paper or plastic box with the proper identification in 
the top rack of the refrigerator (Marked/labeled paper box with the name).  These samples were 
stored properly (labeled/ marked) so that it could be safe while using the refrigerator by other 
research groups as well.  
5) On the day of the measurements, sample storage container tubes with the sample 
were kept above the ice for thawing. (Use white LIFOAM Boxes and you can get ice in the 2nd 
floor of the Natural Science Center (NSC) (on the corridor back of Pete’s office, shop manager) 
and 3rd (Undergraduate biology lab) floors of the same building. Since we are doing label-free 
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analysis, so environmental conditions for all the measurements should be the same (i.e. all samples 
should be dipped in ice immediately taking out from the freezer, before measurement). Multiple 
freezing and unfreezing alter the protein structures, so it is highly recommended to finish all 
measurements in one sitting).  
6) Other issues like the use of cooling gases, (such as He & N2), leaving the sample in 
air, crowded environment of the lab is also taken care of as they are not appropriate for our study.   
Personal Security and Waste Management 
We are analyzing biological (Hazardous) samples, so extreme care is taken while handling 
these samples and while managing related waste products including used gloves, cleaning wipes, 
Pipette tips, glass needles.  
1) Gloves (sometimes masks and lab coats also) were used while handling samples, 
Broken parts, and wastes such as plastic pipette tips, used gloves, glass pipette, Berkshire paper, 
and others. Considering gloves could be the vectors for infection related to these diseases: colitis 
and carcinogenesis, these should not be used when touching anything other than the samples (while 
leaving the room and touching the door handle, mobile phones, computer, water bottle, etc.). 
2) All the used gloves, glass pieces, serum tubes, and wipe-papers are properly 
managed in the appropriate container with biohazard red plastic bags which is kept in our lab 
(Optoelectronics laboratory, 146/148 NSC, GSU). 
3) These waste items were collected in appropriate cardboard boxes as recommended 
by university guideline and are safely discarded.  
 
Spectral Response Measurements 
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The spectral response measurements involve several steps as summarized in the video 
movie (https://www.youtube.com/watch?v=vn1EQ8liI4g) Also I college link ?// 
1) Cleaning: The surface of ATR crystal was first cleaned with sterile phosphate-
buffered saline (SALINE) followed by ETHANOL. For the longevity of diamond crystal, we are 
using Berkshire paper instead of other tissue papers. Wipe saline and ethanol by Berkshire papers 
in an x pattern. Wipe only once in each direction so that other dust molecules attached to the crystal 
surface will be absorbed.  
Note: Change pipette needles fixed with rubber suction for every new experiment (sample) 
to avoid contamination, and gently press the rubber vacuum suction (pump) to pump SALINE and 
ETHANOL. Otherwise, it will come up to rubber surface from the pipette tip and increases the 
chance of contamination.  
2) The cleanliness test was then conducted to ensure there are no signal peaks 
(indicating serum residue or other contaminant signatures) higher than the environmental noise 
level. (Just click on the cleanliness test option). Make sure the light signal path includes the ATR 
crystal.  
3) The Background: Before any experimental measurement, background spectra 
were measured. The background spectrum allows us to get the true values of absorption peaks due 
to molecules present in the sample. Background shows the presence of any environmental residue 
on the crystal surface or in the light path. The spectrum was performed on a clean and empty 
surface before each measurement. It allows us to get high-quality spectra using background 
corrections.  
4) Background Measurement: Open OPUS, by double clicking it. A small window 
will open and use User ID: UPLab1 and Password: OPUS to open.   
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Again, follow the video if there is any confusion during any step of the measurements.  
https://www.youtube.com/watch?v=vn1EQ8liI4g  Also I college  
Press Measure and then repeated measurement. Select, Advanced and choose the path 
where you want to save the date. Remove tick mark on the ATR spectra box of data blocks, for 
background measurement. Fix other parameters like wave number, scan and go back to the Basic 
tab. You will see a repeated sample single channel (lower one). After pressing the repeated 
sample single channel, you will see the IR spectra. Whenever the graphs of spectra start to overlap 
stop the measurement by pressing Abort (right click the green line on the bottom of windows). 
5) Sample measurement: Load the desired amount of sample (I found 1µl is enough 
to cover the ATR crystal) over the crystal plate by using Gilson micropipette carefully. In every 
measurement, sample should have a similar droplet dimension. Also, take care of other 
environmental factors like temperature, pressure, amount of light and other settings (all the 
background conditions) should be similar for every measurement).  
Note: Serum samples (1 µL) are deposited in order to fully cover the crystal surface (I tried 
with 2 µL and 0.5 µL samples and found 1 µL is the best option). 
After loading the sample, click the Advanced button and tick the ATR spectrum, select 
the path, you could change the name from the background you used previously to a new name 
clearly indicating sample identification information. Click on Background you will see an 
arbitrary previous file already selected. Clear (delete) this old background and select the last 
background you took (i.e. the curve just before pressing the abort button). After choosing the 
background, double click load background. Return to the basic button and start scanning by 
pressing the Repeated sample single channel, you will get the IR spectra. Stop your measurement 
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by pressing the Abort button, if you find spectra starts to repeat itself and you have more than 
eight overlapping spectra.   
6) Averaging: Take the average of 6 spectra (Referring: Bayesian statistics), which 
were repeated (i.e. Exactly overlapped) after the serum dries measuring. Each sample was scanned 
multiple times to get ten or higher-quality (exactly overlapping) spectral data within the mid-
infrared range 400 to 4000 cm-1 and 6 reads of the 100 co-added scans for each sample (total of 
600 scans) were averaged. 
7) Number of Scans: Generally, the trend is for the number of scans to go as 2n (n = 
2, 3,4,5…), but we are taking 100 scans for each spectral data. Thus, in each spectrum that are 
selected for the final analysis represents (6x100) 600 scans.  There is not any scientific reason for 
this selection of 100 scans, but my recommendation is use scan 64 instead of 100. (Our experience 
is by choosing 32 scans, will result into noisy spectra, and using 128 scans will take time, so my 
recommendation is to use 64 scans). Depending on the laboratory conditions, these numbers may 
be different. It is thus strongly recommended to check whether everything is ok before going to 
actual measurements.  
8) Spectra saving: If you think you got the best spectra that can represent your 
sample, go to file, save as, mode Data Point Table (.dpt), File name and path, Open them in Excel 
you will get the a set of data, so select columns (A and B), go to Data, text to the column, next, 
comma, next, finish.  
9) Normalization: Normalization is a crucial process while analyzing IR spectral data 
of the present study, as they were recorded under different sample loading, which is influenced by 
fluid dynamics of sample, and drying of sample conditions. Spectral data of the serum samples 
could have different intensity levels. Normalization takes care of variation in IR bands of serum 
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as the spectra were recorded under the same experimental parameters. Herein, Min-max 
normalization of absorbance spectra and the vector normalization of second derivatives spectra 
were performed. Using OPUS 6.5 software, all the spectra were min-max normalized by scaling 
the range 1800 to 900 cm-1. This range is chooses as it comprises a significant biochemical 
fingerprint of the biological material and the amides (I and II) bands[24].   
Vector normalization[135] is another popular protocol. We are using min-max 
normalization in absorbance spectra and vector normalization in second derivative spectra. In the 
following points, I have explained the basic concept of these normalization and mathematical 
formulation, so that one can use desired mathematical programming knowledge while normalizing 
these data.  
10) Min-max normalization: Assuming absorbance values (before normalization) are 
X = x1,x2,x3,x4,…. xn. Find the maximum of them and say Xmax and minimum as Xmin. Min-




   i = 1, 2, 3, …., N.  
The min-max normalized data using this formula is compared as in figure A4 (A) with 
normalized data using OPUS, which guarantees our formula can be used while using other 
programming languages.  
11) Vector normalization: Assuming absorbance values (before normalization) are X 
= x1,x2,x3,x4,…. xn.  
First, find the square of each variable as (x1)2, (x2)2, (x3)2,…. (xn)2. After finding the 
square of variables find the sum of them as; S = (x1)2 + (x2)2 + (x3)2 +…. + (xn)2. Again, find the 




   i = 1, 2, 3, …., N.  
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The vector normalized data using this formula is compared as in figure A4 (B) with 
normalized data using OPUS, which guarantees our formula can be used while using other 
programming languages.  
 
Figure A4 Verifications of mathematical formula for normalization. (A) Min-max 
normalization of absorption spectra. (B) Vector normalization of second derivative curves of the 
spectra. Spectra obtained from the formula overlaps with the corresponding spectra, as obtained 
from the OPUS software. It verifies, these formulas can be used while writing code in another 
programming language.  
12) Smoothing: The second derivatives of Infrared spectra need smoothing.   
The number of data in the absorption curve and the second derivatives curves are equal, so 
by smoothing the number of data points will be same.  Let's say you have data Y = 
(a,b,c,d,e,f,g,h……..z) (i.e. total set of data =26). Now you want to have a smoothed set of data Y’ 
= (a’, b’, c’, d’, …… z’). Here, a’ = (a), b’ = (a+b+c)/3, c’ = (a+b+c+d+e)/5, d’ = 
(a+b+c+d+e+f+g)/7, e’ = (a+b+c+d+e+f+g+h+i)/9, f’ = (b+c+d+e+f+g+h+i+j)/9, ………… q’ = 
(m+n+o+p+q+r+s+t+u)/9, r’ = (n+o+p+q+r+s+t+u+v)/9, …………, v’ = 
(r+s+t+u+v+w+x+y+z)/9, w’ = (t+u+v+w+x+y+z)/7…….. y’ = (x+y+z)/3, z’ =z.  We have nearly 
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3500 sets of data and those crucial for our study lie in the middle, so no need to worry about these 
numbers in the extreme.   
It is noted that we have to smooth only second derivative spectra. In OPUS software, while 
doing second derivatives, there are 9-point smoothing, 12-point smoothing, …. options. We cannot 
get second derivative spectra without smoothing in this software (Note: there is no option available 
to get second derivative spectra without smoothing). Herein, nine-point smoothing is used while 
taking the second derivative spectra. For clarification, a smoothed and unsmoothed spectral data 
using the vector normalized second derivative spectra is shown in figure A5. It is strongly 
recommended to use data before cutting 900-1800 cm-1, as end points are affected during 
smoothing. We can use Adjacent averaging, as explained above or Savitzky-Golay smoothing 
function. The programming languages like Python are using Savitzky-Golay smoothing.  
Look at the left side of the window and change the color of 2-3 last spectra so that you can 
see the difference clearly. If you think you got the best spectra that can represent your sample, go 
to file, save as, mode Data Point Table (.dpt), File name and path, open them in Excel you will get 
the sticking set of data, so select columns (A and B), go to Data, text to the column, next, comma, 





Figure A5 Spectral data before and after smoothing.  
Data Analysis 
The details of spectral analysis techniques are explained in the appropriate section of this 
dissertation.   
1) First, the spectral data of the control and diseased samples within 400-4000 cm-1 
wavenumber range. This mid-IR range includes bio fingerprint region (900-1500 cm-1) and amide 
peaks (1500-1700 cm-1).  
2) Take the average of the final 6 spectra which are overlapped with each other (The 
sample size of at least 6 is needed for meaning full statistical analysis).  
P-value calculation of min-max normalized absorbance: The spectral data of two groups 
(let’s say control and diseased) were first compared using student t-test p-values. In this study we 
are using EXCEL to calculate the p-values and find the p-values at all the wavenumber positions.  
3) Take the second derivatives with 9 point smoothing and do the vector normalize 
them to get the idea of minima and maxima of the data (that will be useful while fitting), for 
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Dendrogram tree diagram plot[63] and PCA[137]. Now vector normalized[135] the second 
derivatives curves.   
4) Hierarchical Cluster Analysis (HCA) and Dendrogram Plot: Our analysis includes 
the dendrogram of HCA, which is commonly employed to identify the similarities between the 
FTIR spectra by using the distances between frequencies and aggregation algorithms[63]. Using 
the “PAST (Paleontological Statistics) 4 - the Past of the Future” software and the vector 
normalized second derivative curve of the absorbance spectra, as input data (variables), HCA is 
performed and the dendrogram is plotted. Dendrogram tree diagram performed, using Ward’s 
algorithm and Euclidian distance measurements, allow us to visualize the overall classification. 
Origin and MATLAB programming were also used for cluster analysis; however, use of PAST-4 
is easy and has necessary inbuilt functions.   
 
Figure A6 Dendrogram tree diagram performed, by using Ward’s algorithm and Euclidian 
distance measurements of vector normalized second derivatives curves within spectral range 
1600-1700 cm-1. (A) A wide difference can be seen between spectra belonging to control and colitis 
mouse, compared to the degree of the dissimilarity between controls and treated while considering 
three groups constraints (1 for control: c1 to c9, 2 for treated: t1 to t9, and 3 colitis: d1 to d9). (B) 
Stratigraphic constraints of three groups showing colitis group has larger heterogeneity form 
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control and treated groups. While there is a similarity between control and treated groups in this 
classification.  
Dendrogram tree diagram performed, using Ward’s algorithm and Euclidian distance 
measurements, allow us to visualize the overall classification as shown in figure A6. In both 
analyses, spectral data from an equal number of mice were used (herein, we have randomly picked 
9 controls). However, the degree of heterogeneity is less for treated groups from control compared 
with colitis while using group constraints as in figure 6A (A). Similarly, only colitis group shows 
strong degree of heterogeneity compared to control and treated groups in stratigraphic constraints. 
Herein, HCA analysis allows us to understand the preliminary idea about the potential application 
of the measurement techniques to segregate the groups.  
5) PCA: PCA[137], a useful statistical analysis[137], is first performed to explain the 
holistic evaluation biomolecular content variations reflected in infrared absorbance data. Using the 
PAST 4 software vector normalized second derivative curve of the absorbance spectra, as input 
data variables, the variance-covariance matrix with the pairwise exclusion of missing values were 
analyzed to get the component plots. This can also be done easily by using Origin and SPSS 
software, but PAST-4 is easier one. The scatter plot of PC1 and PC2 were used to visualize the 
clustering of groups together with different magnitudes and directions. The scree plot is also used 
to check the total variance presented by PC1 and PC2 is significant. These findings from the PCA 
analysis led us to investigate spectral signatures useful in the clinical domain. 
6) Spectral Deconvolution (fitting):  
Watch the video first (https://www.youtube.com/watch?v=zGHP2GBBdnE) and look into 
section 2.4.3, figure 2.1 for details.  
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We perform quantitative analysis of the absorption band values at different spectral 
markers’ positions, which follows discrimination of secondary structures by deconvolution of the 
spectra in the amide I region. During the deconvolution process, the computed curve that best fit 
with the experimental spectrum is obtained from the superposition of Gaussian function energy 
bands (GFEB). The individual bands from deconvolution represent proteins’ secondary structures 
as discussed in the protocol papers, and similar studies in the field[108, 116-118, 120, 126] which 
were used to verify the applicability of this technique over complementary spectroscopic methods 
(X-ray crystallography, and nuclear magnetic resonance).  
The process of deconvolution includes sectioning of min-max normalized spectra followed 
by rubber-band correction with two baseline points, such that absorbance values at extreme ends 
of the selected region will be zero as in figure A6. These spectra were then fitted with GFEBs by 
approximating the position and the number of bands from the minima of second derivative spectra 
and also by the minimization of root mean square error via the Levenberg-Marquardt[138] 
algorithm.  
 
Figure A7 The process of rubber band baseline correction. The sectioned region 1600-
1700 cm-1 is baseline corrected using baseline correction, such that the absorbance at the two 
extreme ends is 0.  
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7) Statistical Analysis: First, student’s t-test is performed in EXCEL to calculate the 
p-value. P-value less than 0.05 (5% in Gaussian distribution) is considered as statistically 
significant in the null hypothesis. It is noted that Bonferroni correction[191] (new p-value, which 
is defined as the ratio of original p-value divided by the number of tests) is also performed to adjust 
type I error[191] (that has higher chances for a false positive; example includes analysis is showing 
differences in similar population due to problematic measurement or analyzing techniques) when 
conducting multiple analysis. It is noted that, using this new p-value, researchers calculate 
statistical power of the study.  
Sensitivity, specificity the receiver operating characteristic (ROC) curves: Quantified 
values of these identifying spectral signatures are statistically analyzed to see the disease-
associated alteration in the sample, and their stabilization after biological therapy. Our statistical 
analysis mainly includes finding the sensitivity and specificity of the signatures for their 
discrimination. Sensitivity and Specificity of a diagnostic test are often used to describe the 
diagnostic accuracy/performance of the analysis in biomedical research[141]. The discriminating 
potential of a diagnostic regimen can be quantified by the Youden index and the area under the 
receiver operating characteristic (ROC) curves [142]. The ROC curve is plotted to find the area 
under curve (AUC). The optimal cutoff value calculated based on the Youden index for each 
spectral marker is used to select the positivity/negativity of the disease and to estimate the 
sensitivity and specificity. Youden Index summarizes the displaying discriminatory accuracy of a 
diagnostic test in ROC curve while distinguishing two populations. It measures the effectiveness 




In this appendix, information about the second derivative spectra is discussed.  
Appendix D.1 Second Derivatives Spectra and Their Importance 
In IR spectroscopy, molecules absorb light at resonance frequencies that are the 
characteristic of molecular structure. Where, the energy of vibration depends on molecular shape 
(potential energy), mass of atoms and the associated vibronic coupling (bonding)[3]. Therefore, 
the observed profile is a convolution of the line profiles of each individual mechanism of 
component constituents. The overall contribution of these individual vibrations is reflected in 
infrared absorbance spectra. Essentially, absorption spectrum is the analysis of the IR light 
interacting with molecules and is visualized in the graph of light absorption on the vertical axis vs 
wavenumber (or wavelength) in horizontal axis.  
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Figure A8 Derivative spectra and their importance for spectral analysis. (A) Gaussian 
function distribution. (B) First derivative spectra and (C) Second derivative spectra. The minima 
position of second derivative spectra exactly represents the maxima of Gaussian Distribution.   
 
The line profiles, which have the shapes of Gaussian, Lorentzian and Voigt functions, 
represent the vibration of individual components and depends on the line position, maximum 
height and half-width. Therefore, curve fitting with these line shapes is sometime preformed either 
for interpolation, or to find the contribution of individual components. The Gaussian distribution 
(function) is used to explain the importance of second derivatives as in figure A7 (A). The first 
and second derivatives of the Gaussian curve are shown figure A7 (B) and figure A7 (C), 
respectively. The minima of second derivative curves exactly represents the maxima of Gaussian 
curve, so minima of second derivatives are used to approximate the number and position of 
GFEB’s used to fit the spectra in our study. These second derivatives data also offer a practical 
and more specific method than routinely used absorption spectrum analysis to obtain the 
composition of proteins and nucleic acids. Therefore, second derivative curves are also used in 










In this appendix, selection of the number of GFEBs (oscillators) for fitting the experimental 
absorbance curves is discussed. Second derivative spectra fitting reflecting the position of protein 
secondary structures is also discussed.  
Appendix E.1 Number of GFEBs (oscillators) 
In IR spectroscopy, the spectra were fitted in general with GFEBs by approximating the 
position and the number of bands from the minima of second derivative spectra and by the 
minimization of root mean square error. ATR-FTIR spectra taken at resolution 8 cm-1, of air-dried 
serum sample at room temperature clearly depicts four valley positions [figure A9(A)] in the 
second derivative spectra showing significant presence of side chain, α-helix, β-sheet and β (anti-
//+turn) structures. Random coil is an integral unit of a protein structures their contribution is 
significant in denatured proteins[193] analysis. However, the sera samples used in our study do 
not have denatured proteins, and our spectra were showing its impact on the infrared absorption is 
negligible compared to other four identified components. It is noted that the denaturation of 
proteins occurs at high temperatures or chemical interactions[193]. In order to be consistent, our 
analysis also includes an additional Gaussian band nearly at 1641 cm-1 reflecting random coil 
structures in protein secondary structures. Figure A9(B) and figure A9(C) shows the experimental 
curve fitting using GFEBs without (n=4) and with (n=5) the inclusion of random coil structures. 
This additional band does not alter the sensitivity or specificity of the identified distinguishing 
markers. Once the band at 1641 cm-1 is included, there is a slight variation in spectral signatures 
(specially, alpha helix/beta sheet) but the pattern of colitis in contrast to non-colitis remains the 
same as discussed, where absorbance spectra were measured at 8cm-1 resolution[4, 5].  
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Figure A9 (A) Second derivative of ATR-FTIR absorbance of control sera at resolution 8 
cm-1, showing the deconvolved amide I region. (B) The individual secondary structure components 
were modeled using GFEB whose positions were determined from the second derivative of the 
absorbance to obtain simulated fits to the experimental curves. (C) Secondary structures were 
modeled using GFEB with the inclusion of random coil components approximately at wavenumber 
position 1641 cm-1 [4]. 
Importantly, with a resolution of 2 cm-1 gives noisy derivative spectra and of 8 cm-1 
resolution gives rise to missing secondary structure information (spectral signatures show a lower 
degree of variability), while using diamond ATR crystal configured to have a single reflection of 
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incident IR radiation. By understanding of the positives and negatives of the techniques[122], and 
their optimizations protocols[123], we found that a resolution of 4 cm-1 allows us to overcome the 
challenges[139] of deconvolution process for quantitative analysis. At this resolution, two 
individual band positions for β-sheet (anti-//) and β-turn are reflected in the second derivative 
spectra. It further allows us to reduce the interspacing distance between bands. Increased spacing 
between individual bands is considered as one of the challenging aspect of fitting technique[139]. 
Figure A10 (A) shows the second derivative spectra of absorbance spectra of air-dried serum 
sample at resolution 4 cm-1. The minima/valley positions in the second derivative spectra showing 
significant presence of side chain, α-helix, β-sheet, β-sheet (anti-//) and β-turn structures.  
 
Figure A10 (A) Second derivative of ATR-FTIR absorbance of control sera at resolution 
4 cm-1, showing amide I, region fitting. (B) The individual secondary structure components were 
126 
modeled using GFEB whose positions were determined from the second derivative of the 
absorbance to obtain simulated fits to the experimental curves. (C) Secondary structures were 
modeled using GFEB with the inclusion of random coil components. 
Experimental absorbance spectra taken at 4 cm-1 resolution were now fitted with (figure 
A10 (C)) and without (figure A10 (B)) random coil structures. The integral ratio of α-helix and β-
sheet protein secondary structures with and without inclusion of random coil structure is analyzed 
using BC data presented on section 3.3 (Figures 3.13 to figure 3.15 above). Figure A11 (A) and 
figure A11 (B) are showing the ratio of the α-helix and β-sheet structures with and without 
including random coils in the fitting. Both figures show the level of β sheet structure increase and 
α helix decrease due to BC.  
 
Figure A11 The integral ratio of α-helix and β-sheet protein secondary structures using 
five and six bands on experimental curves at resolution 4 cm-1. (A) Ratio of integral values while 
fitting experimental curve without random coils structures. (B) Ratio of integral values while 
fitting experimental curves with including random coils structures.  
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Appendix E.2 Estimation of Bands’ Position Using Second Derivatives Spectra Fitting 
The second derivatives of absorbance spectra were also used to extract protein secondary 
structural information reflected in infrared spectral data[194]. The local minima position of the 
second derivative curves of the absorbance spectra provides the position of GFEB bands while 
analyzing absorbance data. Figure A12 shows the techniques for the estimation of the band's 
position using the second derivative fitting. Figure A12 (A) shows the second derivative spectra 
of the experimental absorbance spectrum. The values of the second derivative spectra were 
subtracted from 1 (Figure A12 (B)) at each wavenumber position and were rubber band corrected 
(Figure A12 (C)). Thus obtained rubber band corrected spectra are then fitted with Gussiand bands 
as shown in figure A12 (D). These second derivative spectral fitting offers a practical method to 
obtain supporting information about the chemical composition within the sample. However, the 
second derivative spectra may not provide all the biochemical components, like random coil 
structures; in the considered range as discussed above (figure A9-figure A11). It could be due to 
various reasons such as negligible presence of such protein structures or negligible contribution of 




Figure A12 Second derivative curve fitting technique. (A) Second derivative spectra. (B) 
Values of second derivative spectra subtracted from one at each wavenumber position. (C) Rubber 
band correction of the curve obtained from one minus second derivative. (D) GFEBs fitting to 
estimate the position of the bands.    
